ME01507B - Imidazotriazini i imidazopirimidini kao inhibitori kinaze - Google Patents

Imidazotriazini i imidazopirimidini kao inhibitori kinaze

Info

Publication number
ME01507B
ME01507B MEP-2013-35A MEP3513A ME01507B ME 01507 B ME01507 B ME 01507B ME P3513 A MEP3513 A ME P3513A ME 01507 B ME01507 B ME 01507B
Authority
ME
Montenegro
Prior art keywords
imidazo
quinolin
ylcyclopropyl
pyrimidin
benzamide
Prior art date
Application number
MEP-2013-35A
Other languages
English (en)
Inventor
Jincong Zhuo
Brian Metcalf
Meizhong Xu
Chunhong He
Colin Zhang
Ding-Quan Qian
David M Burns
Yunlong Li
Wenqing Yao
Original Assignee
Incyte Holdings Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39166437&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ME01507(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Incyte Holdings Corp filed Critical Incyte Holdings Corp
Publication of ME01507B publication Critical patent/ME01507B/me

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Claims (66)

1.Spoj formule 1: ili njegova farmaceutski prihvatljiva sol ili njegov predlijek, naznačeni time da: A je N ili CR3; i (a) pri čemu, kada A je N; Cy1 je aril, heteroaril, cykloalkil, ili heterocikloalkil, svaki izborno zamijenjen s 1, 2, 3, 4 ili 5 -W-X-Y-Z; Cy2 je aril, heteroaril, cikloalkil, ili heterokicloalkil, svaki izborno zamijenjen s 1, 2, 3, 4 ili 5 -W’-X’-Y’-Z’; L1 je CH2, CH2CH2, cikloalkilen, O ili S L2 je (CR7R8)r, (CR7R8)s-(cikloalkilen)-(CR7R8)t, (CR7R8)s-(arilen)-(CR7R8)t, (CR7R8)s-(heteroci- kloalkilen)-(CR7R8)t, (CR7R8)s-(heteroarilen)-(CR7R8)t, (CR7R8)sO(CR7R8)t, (CR7R8)sS(CR7R8)t, (CR7R8)sC(O)(CR7R8)t, (CR7R8)sC(O)NR9(CR7R8)t, (CR7R8)sC(O)O(CR7R8)t, (CR7R8)sOC(O)(CR7R8)t, (CR7R8)sOC(O)NR9(CR7R8)t, (CR7R8)sNR9(CR7R8)t, (CR7R8)sNR9C(O)NR9(CR7R8)t, (CR7R8)sS(O) (CR7R8)t, (CR7R8)sS(O)NR7(CR8R9)t, (CR7R8)sS(O)2(CR7R8)t, or (CR7R8)sS(O)2NR9(CR7R8)t, pri čemu je navedeni cikloalkilen, arilen, heterocikloalkilen, ili heteroarilen izborno zamijenjen s 1, 2 ili 3 supstituenta nezavisno odabrana od Cy4, halo, C1-6 alkila, C2-6 alkenila, C2-6 alkinila, C1-6 haloalkila, halosulfanila, CN, NO2, N3, ORa1, SRa1, C(O)Rb1, C(O)NRc1Rd1, C(O)ORa1, OC(O)Rb1, OC(O)NRc1Rd1, NRc1Rd1, NRc1C(O)Rb1, NRc1C(O)NRc1Rd1, NRc1C(O)ORa1, C(=NRg)NRc1Rd1, NRc1C(=NRg)NRc1Rd1, P(Rf1)2, P(ORe1)2, P(O)Re1Rf1, P(O)ORe1ORf1, S(O)Rb1, S(O)NRc1Rd1, S(O)2Rb1, NRc1S(O)2Rb1, i S(O)2NRc1Rd1; R1 je H ili ⎯W"-X"-Y"-Z"; R2 je H, halo, C1-6 alkil, C2-6 alkenil, C2-6 alkinil, C1-6 haloalkil, CN, NO2, ORA, SRA, C(O)RB, C(O)NRCRD, C(O)ORA, OC(O)RB, OC(O)NRCRD, NRCRD, NRCC(O)RB, NRCC(O)NRCRD, NRCC(O)ORA, S(O)RB, S(O)NRCRD, S(O)2RB, NRCS(O)2RB ili S(O)2NRCRD; R3 je H, cikloalkil, aril, heterocikloalkil, heteroaril, halo, C1-6 alkil, C2-6 alkenil, C2-6 alkinil, C1-6 haloalkil, CN, NO2, ORA, SRA, C(O)RB, C(O)NRCRD, C(O)ORA, OC(O)RB, OC(O)NRCRD, NRCRD, NRCC(O)RB, NRCC(O)NRCRD, NRCC(O)ORA, S(O)RB, S(O)NRCRD, S(O)2RB, NRCS(O)2RB i S(O)2NRCRD; gdje je navedeni cikloalkil, aril, heterocikloalkil, heteroaril ili C1-6 alkil izborno zamijenjen s 1,2 ili 3 supstituenta nezavisno odabrana od Cy5, halo, C1-6 alkila, C2-6 alkenila, C2-6 alkinila, C1-6 haloalkila, halosulfanila, CN, NO2, N3, ORa1, SRa1, C(O)Rb1, C(O)NRc1Rd1, C(O)ORa1, OC(O)Rb1, OC(O)NRc1Rd1, NRc1Rd1, NRc1C(O)Rb1, NRc1C(O)NRc1Rd1, NRc1C(O)ORa1, C(=NRg)NRc1Rd1, NRc1C(=NRg)NRc1Rd1, P(Rf1)2, P(ORe1)2, P(O)Re1Rf1, P(O)ORe1ORf1, S(O)Rb1, S(O)NRc1Rd1, S(O)2Rb1, NRc1S(O)2Rb1 i S(O)2NRc1Rd1; ili R2 i ⎯L2-Cy2 su povezani zajedno kako bi formirali skupinu formule: pri čemu je prsten B fuzionirani arilni ili fuzionirani heteroarilni prsten, svaki izborno zamijenjen s 1, 2 ili 3 -W’-X’-Y’-Z’; R4 je nezavisno odabran od H, halo, OH, C1-6 alkila, C2-6 alkenila, C2-6 alkinila, C1-6 alkoksija, alkoksialkila, cianoalkila, heterocikloalkila, cikloalkila, C1-6 haloalkila, CN, i NO2; R7 i R8 su nezavisno odabrani od H, halo, OH, C1-6 alkila, C2-6 alkenila, C2-6 alkinila, C1-6 alkoksija, C1-6 haloalkila, CN i NO2; ili R7 i R8 zajedno s C atomom za koji su povezani formiraju 3, 4, 5, 6 ili 7-člani cikloalkilni ili heterocikloalkilni prsten, svaki izborno zamijenjen s 1, 2 ili 3 supstituenta nezavisno odabrana od halo, OH, C1-6 alkila, C2-6 alkenila, C2-6 alkinila, C1-6 alkoksija, C1-6 haloalkila, CN i NO2; R9 je H, C1-6 alkila, C2-6 alkenila ili C2-6 alkinila; W, W’ i W" su nezavisno odsutni ili nezavisno odabrani od C1-6 alkilena, C2-6 alkenilena, C2-6 alkinilena, O, S, NRh, CO, COO, CONRh, SO, SO2, SONRh i NRhCONRi, pri čemu je svaki od C1-6 alkilena, C2-6 alkenilena i C2-6 alkinilena izborno zamijenjen s 1, 2 ili 3 supstituenta odabrana od halo, C1-6 alkila, C1-6 haloalkila, OH, C1-6 alkoksija, C1-6 haloalkoksija, amina, C1-6 alkilamina i C2-8 dialkilamina; X, X’ i X" su nezavisno odsutni ili nezavisno odabrani od C1-6 alkilena, C2-6 alkenilena, C2-6 alkinilena, arilena, cikloalkilena, heteroarilena i heterocikloalkilena, pri čemu svaki od C1-6 alkilena, C2-6 alkenilena, C2-6 alkinilena, arilena, cikloalkilena, heteroarilena i heterocikloalkilena je izborno zamijenjen s 1, 2 ili 3 supstituenta nezavisno odabrana od halo, CN, NO2, OH, C1-6 alkila, C1-6 haloalkila, C2-8 alkoksialkila, C1-6 alkoksija, C1-6 haloalkoksija, C2-8 alkoksialkoksija, cikloalkila, heterocikloalkila, C(O)ORj, C(O)NRhRi, amina, C1-6 alkilamina i C2-8 dialkilamina; Y, Y’ i Y" su nezavisno odsutni ili nezavisno odabrani od C1-6 alkilena, C2-6 alkenilena, C2-6 alkinilena, O, S, NRh, CO, COO, CONRh, SO, SO2, SONRh, i NRhCONRi, pri čemu je svaki od C1-6 alkilena, C2-6 alkenilena i C2-6 alkinilena izborno zamijenjen s 1, 2 ili 3 supstituenta nezavisno odabrana od halo, C1-6 alkila, C1-6 haloalkila, OH, C1-6 alkoksija, C1-6 haloalkoksija, amina, C1-6 alkilamina i C2-8 dialkilamina; Z, Z’ i Z" su nezavisno odabrani od H, halo, C1-6 alkila, C2-6 alkenila, C2-6 alkinila, C1-6 haloalkila, halosulfanila, CN, NO2, N3, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)NRc2Rd2, NRc2C(O)ORa2, C(=NR9)NRc2Rd2, NRc2C(=NR9)NRc2Rd2, P(Rf2)2, P(ORe2)2, P(O)Re2Rf2, P(O)ORe2ORf2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, NRc2S(O)2Rb2, S(O)2NRc2Rd2, arila, cikloalkila, heteroarila i heterocikloalkila, gdje su navedeni C1-6 *alkil, C2-6 alkenil, C2-6 alkinil, aril, cikloalkil, heteroaril i heterocikloalkil izborno zamijenjeni s 1, 2, 3, 4 ili 5 supstituenta nezavisno odabrana od halo, C1-6 alkila, C2-6 alkenila, C2-6 alkinila, C1-6 haloalkila, halosulfanila, CN, NO2, N3, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)NRc2Rd2, NRc2C(O)ORa2, C(=NRg)NRc2Rd2, NRc2C(=NRg)NRc2Rd2, P(Rf2)2, P(ORe2)2, P(O)Re2Rf2, P(O)ORe2ORf2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2 , NRc2S(O)2Rb2 i S(O)2NRc2Rd2; pri čemu dva susjedna ⎯W-X-Y-Z, zajedno s atomima s kojima su povezani, izborno formiraju fuzionirani cikloalkilni prsten od 4-20 članova ili fuzionirani heterocikloalkilni prsten od 4-20 članova, svaki izborno zamijenjen s 1, 2 ili 3 supstituenta nezavisno odabrana od halo, C1-6 alkila, C2-6 alkenila, C2-6 alkinila, C1-6 haloalkila, halosulfanila, CN, NO2, ORa3, SRa3, C(O)Rb3, C(O)NRc3Rd3, C(O)ORa3, OC(O)Rb3, OC(O)NRc3Rd3, NRc3Rd3, NRc3C(O)Rb3, NRc3C(O)NRc3Rd3, NRc3C(O)ORa3, C(=NRg)NRc3Rd3, NRc3C(=NRg)NRc3Rd3, S(O)Rb3, S(O)NRc3Rd3, S(O)2Rb3, NRc3S(O)2Rb3, S(O)2NRc3Rd3, arila, cikloalkila, heteroarila i heterocikloalkila; pri čemu dva susjedna ⎯W’-X’-Y’-Z’, zajedno s atomima s kojima su povezani, izborno formiraju fuzionirani cikloalkilni prsten od 4-20 članova ili spojeni heterocikloalkilni prsten od 4-20 članova, svaki izborno zamijenjen s 1, 2 ili 3 supstituenta nezavisno odabrana od halo, C1-6 alkila, C2-6 alkenila, C2-6 alkinila, C1-6 haloalkila, halosulfanila, CN, NO2, ORa3, SRa3, C(O)Rb3, C(O)NRc3Rd3, C(O)ORa3, OC(O)Rb3, OC(O)NRc3Rd3, NRc3Rd3 , NRc3C(O)Rb3, NRc3C(O)NRc3Rd3, NRc3C(O)ORa3, C(=NRg)NRc3Rd3, NRc3C(=NRg)NRc3Rd3, S(O)Rb3, S(O)NRc3Rd3, S(O)2Rb3, NRc3S(O)2Rb3, S(O)2NRc3Rd3, arila, cikloalkila, heteroarila i heterocikloalkila; Cy4 i Cy5 su nezavisno odabrani od arila, cikloalkila, heteroarila i heterocikloalkila, svaki izborno zamijenjen s 1, 2, 3, 4 ili 5 supstituenta nezavisno odabrana od halo, C1-6 alkila, C2-6 alkenila, C2-6 alkinila, C1-6 haloalkila, halosulfanila, CN, NO2, N3, ORa4, SRa4, C(O)Rb4, C(O)NRc4Rd4, C(O)ORa4, OC(O)Rb4, OC(O)NRc4Rd4, NRc4Rd4, NRc4C(O)Rb4, NRc4C(O)NRc4Rd4, NRc4C(O)ORa4, C(=NRg)NRc4Rd4, NRc4C(=NRg)NRc4Rd4, P(Rf4)2, P(OR4)2, P(O)Re4Rf4, P(O)ORe4ORf4, S(O)b4, S(O)NRc4Rd4, S(O)2Rb4, NRc4S(O)2Rb4 i S(O)2NRc4Rd4; RA je H, C1-4 alkil, C2-4 alkenil, C2-4 alkinil, cikloalkil, heterocikloalkil, aril ili heteroaril gdje je navedeni C1-4 alkil, C2-4 alkenil, C2-4 alkinil, cikloalkil, heterocikloalkil, aril ili heteroaril izborno zamijenjen s 1, 2 ili 3 supstituenta nezavisno odabrana od OH, CN, amino, halo i C1-4 alkila; RB je H, C1-4 alkil, C2-4 alkenil, C2-4 alkinil, cicloalkil, heterocikloalkil, aril, ili heteroaril gdje je navedeni C1-4 alkil, C2-4 alkenil, ili C2-4 alkinil, cikloalkil, heterocikloalkil, aril, ili heteroaril izborno zamijenjen s 1, 2 ili 3 supstituenta nezavisno odabrana od OH, CN, amino, halo i C1-4 alkila; RC i RD su nezavisno odabrana od H, C1-4 alkila, C2-4 alkenila, ili C2-4 alkinila, gdje je navedeni C1-4 alkil, C2-4 alkenil, ili C2-4 alkinil izborno zamijenjen s 1, 2 ili 3 supstituenta nezavisno odabrana od OH, CN, amino, halo i C1-4 alkila; ili RC i RD zajedno s N atomom s kojim su povezani formiraju 4-, 5-, 6- ili 7-članu heterocikloalkilnu skupinu ili heteroarilnu skupinu, svaku izborno zamijenjenu s 1, 2 ili 3 supstituenta nezavisno odabrana od OH, CN, amino, halo i C1-4 alkila; Ra, Ra1, Ra2, Ra3, i Ra4 su nezavisno odabrani od H, C1-6 alkila, C1-6 haloalkila, C2-6 alkenila, C2-6 alkinila, arila, cikloalkila, heteroarila, heterocikloalkila, arilalkila, heteroarilalkila, cikloalkilalkila i heterocikloalkilalkila, gdje je navedeni C1-6 alkil, C1-6 haloalkil, C2-6 alkenil, C2-6 alkinil, aril, cikloalkil, heteroaril, heterocikloalkil, arilalkil, heteroarilalkil, cikloalkilalkil, ili heterocikloalkilalkil izborno zamijenjen s 1, 2 ili 3 supstituenta nezavisno odabrana od OH, CN, amino, halo, C1-6 alkila, C1-6 alkoksija, C1-6 haloalkila i C1-6 haloalkoksija; Rb, Rb1, Rb2, Rb3 i Rb4 su nezavisno odabrani od H, C1-6 alkila, C1-6 haloalkila, C2-6 alkenila, C2-6 alkinila, arila, cikloalkila, heteroarila, heterocikloalkila, arilalkila, heteroarilalkila, cikloalkilalkila i heterocikloalkilalkila, pri čemu je navedeni C1-6 alkil, C1-6 haloalkil, C2-6 alkenil, C2-6 alknil, aril, cikloalkil, heteroaril, heterocikloalkil, arilalkil, heteroarilalkil, cikloalkilalkil ili heterocikloalkilalkil izborno zamijenjen s 1, 2 ili 3 supstituenta nezavisno odabrana od OH, CN, amino, halo, C1-6 alkila, C1-6 alkoksija, C1-6 haloalkila i C1-6 haloalkoksija; Rc i Rd su nezavisno odabrani od H, C1-10 alkila, C1-6 haloalkila, C2-6 alkenila, C2-6 alkinila, arila, heteroarila, cikloalkila, heterocikloalkila, arilalkila, heteroarilalkila, cikloalkilalkila ili heterocikloalkilalkila, pri čemu je navedeni C1-10 alkil, C1-6 haloalkil, C2-6 alkenil, C2-6 alkinil, aril, heteroaril, cikloalkil, heterocikloalkil, arilalkil, heteroarilalkil, cikloalkilalkil ili heterocikloalkilalkil izborno zamijenjen s 1, 2 ili 3 supstituenta nezavisno odabrana od OH, CN, amino, halo, C1-6 alkila, C1-6 alkoksija, C1-6 haloalkila i C1-6 haloalkila; ili Rc i Rd zajedno s N atomom s kojim su povezani formiraju 4-, 5-, 6- ili 7-članu heterocikloalkilnu skupinu ili heteroarilnu skupinu, svaku izborno zamijenjenu s 1, 2 ili 3 supstituenta nezavisno odabrana od OH, CN, amino, halo, C1-6 alkila, C1-6 alkoksija, C1-6 haloalkila i C1-6 haloalkoksija; Rc1 i Rd1 su nezavisno odabrani od H, C1-10 alkila, C1-6 haloalkila, C2-6 alkenila, C2-6 alkinila, arila, heteroarila, cicloalkila, heterocikloalkila, arilalkila, heteroarilalkila, cikloalkilalkila ili heterocikloalkilalkila, pri čemu je navedeni C1-10 alkil, C1-6 haloalkil, C2-6 alkenil, C2-6 alkinil, aril, heteroaril, cikloalkil, heterocikloalkil, arilalkil, heteroarilalkil, cicloalkilalkil ili heterocicloalkilalkil izborno zamijenjen s 1, 2 ili 3 supstituenta nezavisno odabrana od OH, CN, amino, halo, C1-6 alkila, C1-6 alkoksija, C1-6 haloalkila, i C1-6 haloalkoksija; ili Rc1 i Rd1 zajedno s N atomom s kojim su povezani formiraju 4-, 5-, 6- ili 7-članu heterocikloalkilnu skupinu ili heteroarilnu skupinu, svaku izborno zamijenjenu s 1, 2 ili 3 supstituenta nezavisno odabrana od OH, CN, amino, halo, C1-6 alkila, C1-6 alkoksija, C1-6 haloalkila i C1-6 haloalkoksija; Rc2 i Rd2 su nezavisno odabrani od H, C1-10 alkila, C1-6 haloalkila, C2-6 alkenila, C2-6 alkinila, arila, heteroarila, cikloalkila, heterocikloalkila, arilalkila, heteroarilalkila, cikloalkilalkila, heterocikloalkilalkila, arilcikloalkila, arilheterocikloalkila, arilheteroarila, biarila, heteroarilcikloalkila, heteroarilheterocikloalkila, heteroarilarila i biheteroarila, pri čemu je navedeni C1-10 alkil, C1-6 haloalkil, C2-6 alkenil, C2-6 alkinil, aril, heteroaril, cikloalkil, heterocikloalkil, arilalkil, heteroarilalkil, cikloalkilalkil, heterocikloalkilalkil, arilcikloalkil, arilheterocikloalkil, arilheteroaril, biaril, heteroarilcikloalkil, heteroarilheterocikloalkil, heteroarilaril i biheteroaril svaki izborno zamijenjen s 1, 2 ili 3 supstituenta nezavisno odabrana od OH, CN, amino, halo, C1-6 alkila, C1-6 alkoksija, C1-6 haloalkila, C1-6 haloalkoksija, hidroksialkila, cianoalkila, arila, heteroarila, C(O)ORa4, C(O)Rb4, S(O)2Rb3,alkoksialkila i alkoksialkoksija; ili Rc2 ili Rd2 zajedno sa N atomom s kojim su povezani formiraju 4-, 5-, 6- ili 7-članu heterocikloalkilnu skupinu ili heteroarilnu skupinu, svaku izborno zamijenjenu s 1, 2 ili 3 supstituenta nezavisno odabrana od OH, CN, amino, halo, C1-6 alkila, C1-6 alkoksija, C1-6 haloalkila, C1-6 haloalkoksija, hidroksialkila, cianoalkila, arila, heteroarila, C(O)ORa4, C(O) Rb4, S(O)2Rb3, alkoksialkila i alkoksialkoksija; Rc3 i Rd3 su nezavisno odabrani od H, C1-10 alkila, C1-6 haloalkila, C2-6 alkenila, C2-6 alkinila, arila, heteroarila, cikloalkila, heterocikloalkila, arilalkila, heteroarilalkila, cikloalkilalkila ili heterocikloalkilalkila, pri čemu je navedeni C1-10 alkil, C1-6 haloalkil, C2-6 alkenil, C2-6 alkinil, aril, heteroaril, cikloalkil, heterocikloalkil, arilalkil, heteroarilalkil, cikloalkilalkil ili heterocikloalkilalkil izborno zamijenjen s 1, 2 ili 3 supstituenta nezavisno odabrana od OH, CN, amino, halo, C1-6 alkila, C1-6 alkoksija, C1-6 haloalkila i C1-6 haloalkoksi; ili Rc3 i Rd3 zajedno s N atomom s kojim su povezani formiraju 4-, 5-, 6- ili 7-članu heterocikloalkilnu skupinu ili heteroarilnu skupinu, svaku izborno zamijenjenu s 1, 2 ili 3 supstituenta nezavisno odabrana od OH, CN, amino, halo, C1-6 alkila, C1-6 alkoksija, C1-6 haloalkila i C1-6 haloalkoksija; Rc4 i Rd4 su nezavisno odabrani od H, C1-10 alkila, C1-6 haloalkila, C2-6 alkenila, C2-6 alkinila, arila, heteroarila, cikloalkila, heterocikloalkila, arilalkila, heteroarilalkila, cikloalkilalkila ili heterocikloalkilalkila, pri čemu je navedeni C1-10 alkil, C1-6 haloalkil, C2-6 alkenil, C2-6 alkinil, aril, heteroaril, cikloalkil, heterocikloalkil, arilalkil, heteroarilalkil, cikloalkilalkil ili heterocikloalkilalkil izborno zamijenjen s 1, 2 ili 3 supstituenta nezavisno odabrana od OH, CN, amino, halo, C1-6 alkila, C1-6 alkoksija, C1-6 haloalkila, i C1-6 haloalkoksija; ili Rc4 i Rd4 zajedno sa N atomom s kojim su povezani formiraju 4-, 5-, 6- ili 7-članu heterocikloalkilnu skupinu ili heteroarilnu skupinu, svaku izborno zamijenjen s 1, 2 ili 3 supstituenta nezavisno odabrana od OH, CN, amino, halo, C1-6 alkila, C1-6 alkoksija, C1-6 haloalkila i C1-6 haloalkoksija; Re, Re1, Re2 i Re4 su nezavisno odabrani od H, C1-6 alkila, C1-6 haloalkila, C2-6 alkenila, (C1-6 alkoksi)-C1-6 alkila, C2-6 alkinila, arila, cikloalkila, heteroarila, heterocikloalkila, arilalkila, cikloalkilalkila, heteroarilalkila i heterocikloalkilalkila; Rf, Rf1, Rf2 i Rf4 su nezavisno odabrani od H, C1-6 alkila, C1-6 haloalkila, C2-6 alkenila, C2-6 alkinila, arila, cikloalkila, heteroarila i heterocikloalkila; Rg je H, CN i NO2; Rh i Ri su nezavisno odabrani od H i C1-6 alkila; Rj je H, C1-6 alkil, C1-6 haloalkil, C2-6 alkenil, C2-6 alkinil, aril, cikloalkil, heteroaril, heterocikloalkil, arilalkil, heteroarilalkil, cikloalkilalkil ili heterocikloalkilalkil; r je 0, 1, 2, 3, 4, 5 ili 6; s je 0, 1, 2, 3 ili 4; i t je 0, 1, 2, 3 ili 4; i (b) pri čemu, kada je A CR3: L’ je cikloalkilen, O ili S; a sve druge varijable su definirane kao pod (a)
2.Spoj prema zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačeni time da A jest N.
3.Spoj prema zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačeni time da A jest CR3.
4.Spoj prema zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačeni time da A jest CH.
5.Spoj prema zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačeni time da Cy1 jest aril ili heteroaril, svaki izborno zamijenjen s 1, 2, 3, 4 ili 5 -W-X-Y-Z.
6.Spoj prema zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačeni time da Cy1 jest aril izborno zamijenjen s 1, 2, 3, 4 ili 5 -W-X-Y-Z.
7.Spoj prema zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačen time da Cy1 jest heteroaril izborno zamijenjen s 1, 2, 3, 4 ili 5 -W-X-Y-Z.
8.Spoj prema zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačeni time da Cy1 jest kinonlinil izborno zamijenjen s 1, 2, 3, 4 ili 5 -W-X-Y-Z.
9.Spoj prema zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačeni time da Cy1 jest kinolinil.
10.Spoj prema zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačeni time da Cy2 jest aril ili heteroaril, svaki izborno zamijenjen s 1, 2, 3, 4 ili 5 -W’-X’-Y’-Z’.
11.Spoj prema zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačeni time da Cy2 jest aril ili heteroaril, svaki izborno zamijenjen s 1, 2, 3, 4 ili 5 -W’-X’-Y’-Z’ pri čemu najmanje jedan od navedenih -W’-X’-Y’-Z’ je C(O)NRc2Rd2.
12.Spoj prema zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačeni time da Cy2 jest aril izborno zamijenjen s 1, 2, 3, 4 ili 5 -W’-X’-Y’-Z’.
13.Spoj prema zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačeni time da Cy2 jest heteroaril izborno zamijenjen s 1, 2, 3, 4 ili 5 -W’-X’-Y’-Z’.
14.Spoj prema zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačeni time da L1 jest O ili S.
15.Spoj prema zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačeni time da L1 jest CH2 ili CH2CH2 ili cikloalkilen.
16.Spoj prema zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačeni time da L1 jest CH2 ili ciklopropilen.
17.Spoj prema zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačeni time da L1 jest cikloalkilen.
18.Spoj prema zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačeni time da L1 jest ciklopropilen.
19.Spoj prema zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačeni time da L2 jest (CR7R8)r.
20.Spoj prema zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačeni time da L2 jest (CR7R8)r i r je 0.
21.Spoj prema zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačeni time da L2 jest (CR7R8)r, (CR7R8)s-(cikloalkilen)-(CR7R8)t, (CR7R8)s-(arilen)-(CR7R8)t,(CR7R8)s-(heterocikloalkilen)-(CR7R8)t ili (CR7R8)s-(heteroarilen)-(CR7R8)t, gdje je navedeni cikloalkilen, arilen, heterocikloalkilen ili heteroarilen izborno zamijenjen s 1, 2 ili 3 supstituenta nezavisno odabrana od Cy4, halo, C1-6 alkila, C2-6 alkenila, C2-6 alkinila, C1-6 haloalkila, halosulfanila, CN, NO2, N3, ORa1, SRa1, C(O)Rb1, C(O)NRc1Rd1, C(O)ORa1, OC(O)Rb1, OC(O)NRc1Rd1, NRc1Rd1, NRc1C(O)Rb1, NRc1C(O)NRc1Rd1, NRc1C(O)ORa1, C(=NRg)NRc1Rd1, NRc1C(=NRg)NRc1Rd1, P(Rf1)2, P(ORe1)2, P(O)Re1Rf1, P(O)ORelORfi, S(O)Rb1, S(O)NRc1Rd1, S(O)2Rb1, NRc1S(O)2Rb1, i S(O)2NRc1Rd1.
22.Spoj prema zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačeni time da L2 jest (CR7R8)r, (CR7R8)s-(cikloalkilen)-(CR7R8)t ili (CR7R8)-(arilen)-(CR7R8)t, gdje je navedeni cikloalkilen ili arilen izborno zamijenjen s 1, 2 ili 3 supstituenta nezavisno odabrana od Cy4, halo, C1-6 alkila, C2-6 alkenila, C2-6 alkinila, C1-6 haloalkila, halosulfanila, CN, NO2, N3, ORa1, SRa1, C(O)Rb1, C(O)NRclRad1, C(O)ORa1, OC(O)Rb1, OC(O)NRc1Rd1, NRc1Rd1, NRc1C(O)Rb1, NRc1C(O)NRc1Rd1, NRc1C(O)ORa1, C(=NRg)NRc1Rd1, NRc1C(=NRg)NRc1Rd1, P(Rf1)2, P(ORe1)2,P(O)Re1Rf1, P(O)ORe1ORf1, S(O)Rb1, S(O)NRc1Rd1, S(O)2Rb1, NRc1S(O)2Rb1 i S(O)2NRc1Rd1.
23.Spoj prema zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačeni time da L2 jest (CR7R8)s-(cikloalkilen)-(CR7R8)t ili (CR7R8)s-(arilen)-(CR7R8)t, gdje je navedeni cikloalkilen ili arilen izborno zamijenjen s 1, 2 ili 3 supstituenta nezavisno odabrana od Cy4, halo, C1-6 alkila, C2-6 alkenila, C2-6 alkinila, C1-6 haloalkila, halosulfanila, CN, NO2, N3, ORa1, SRa1, C(O)Rb1, C(O)NRc1Rd1, C(O)ORa1, OC(O)Rb1, OC(O)NRc1Rd1, NRc1Rd1, NRc1C(O)Rb1, NRc1C(O)NRc1Rd1, NRc1C(O)ORa1, C(=NRg)NRc1Rd1, NRc1C(=NRg)NRc1Rd1, P(Rf1)2, P(ORe1)2, P(O)Re1Rf1. P(O)ORe1ORf1, S(O)Rb1, S(O)NRc1Rd1, S(O)2Rb1, NRc1S(O)2 Rb1 i S(O)2NRc1Rd1.
24.Spoj prema zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačeni time da L2 jest cikloalkilen ili arilen.
25.Spoj prema zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačeni time da L2 jest arilen.
26.Spoj prema zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačeni time da Cy2 jest aril izborno zamijenjen s 1, 2, 3, 4 ili 5 -W’-X’-Y’-Z’.
27.Spoj prema zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačeni time da Cy2 jest heteroaril izborno zamijenjen s 1, 2, 3, 4 ili 5 -W’-X’-Y’-Z’.
28.Spoj prema zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačeni time da Cy2 jest cikloalkil izborno zamijenjen s 1, 2, 3, 4 ili 5 -W’-X’-Y’-Z’.
29.Spoj prema zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačeni time da Cy2 jest heterocikloalkil izborno zamijenjen s 1, 2, 3, 4 ili 5 -W’-X’-Y’-Z’.
30.Spoj prema zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačeni time da R1 jest H.
31.Spoj prema zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačeni time da R2 jest H.
32.Spoj prema zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačeni time da R3 jest H.
33.Spoj prema zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačeni time da R4 jest H.
34.Spoj prema zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačeni time da R7 jest H.
35.Spoj prema zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačeni time da R8 jest H.
36.Spoj prema zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačeni time da R9 jest H.
37.Spoj prema zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačeni time da -W-X-Y-Z jest halo, C1-6 alkil, C2-6 alkenil, C2-6 alkinil, C1-6 haloalkil, halosulfanil, CN, NO2, N3, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)NRc2Rd2, NRc2C(O)ORa2, C(=NRg)NRc2Rd2, NRc2C(=NRg)NRc2Rd2, P(Rf2)2, P(ORe2)2, P(O)Re2Rf2, P(O)ORe2ORf12, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, NRc2S(O)2Rb2, S(O)2NRc2Rd2, aril, cikloalkil, heteroaril i heterocicloalkil, pri čemu je navedeni C1-6 alkil, C2-6 alkenil, C2-6 alkinil, aril, cikloalkil, heteroaril i heterocikloalkil izborno zamijenjen s 1, 2, 3, 4 ili 5 supstituenta nezavisno odabrana od halo, C1-6 alkila, C2-6 alkenila, C2-6 alkinila, C1-6 haloalkila, halosulfanila, CN, NO2, N3, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)NRc2Rd2, NRc2C(O)ORa2, C(=NRg)NRc2Rd2, NRc2C(=NRg)NRc2Rd2, P(Rf2)2, P(ORe2)2, P(O)Re2Rf2, P(O)ORe2ORf2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2,NRc2S(O)2Rb2 i S(O)2NRc2Rd2.
38.Spoj prema zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačeni time da -W-X-Y-Z jest halo, C1-6 alkil, C2-6 alkenil, C2-6 alkinil, C1-6 haloalkil, halosulfanil, CN, NO2, N3, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)NRc2Rd2, NRc2C(O)ORa2, C(=NRg)NRc2Rd2, NRc2C(=NRg)NRc2Rd2, P(Rf2)2, P(ORe2)2, P(O)Re2Rf2, P(O)ORe2ORf2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, NRc2S(O)2Rb2 ili S(O)2NRc2Rd2.
39.Spoj prema zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačeni time da -W-X-Y-Z jest halo, C1-6 alkil, C1-6 haloalkil, CN, NO2, N3 ili ORa2.
40.Spoj prema zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačeni time da –W-X-Y-Z jest ORa2.
41.Spoj prema zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačeni time da –W-X-Y-Z jest metoksi.
42.Spoj prema zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačeni time da – W’-X’-Y’-Z’ jest halo, C1-6 alkil, C2-6 alkenil, C2-6 alkinil, C1-6 haloalkil, halosulfanil, CN, NO2, N3, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)NRc2Rd2, NRc2C(O)ORa2, C(=NRg)NRc2Rd2, NRc2C(=NRg)NRc2Rd2, P(Rf2)2, P(ORe2)2, P(O)Re2Rf2, P(O)ORe2ORf2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, NRc2S(O)2Rb2, S(O)2NRc2Rd2, aril, cikloalkil, heteroaril i heterocikloalkil, pri čemu je navedeni C1-6 alkil, C2-6 alkenil, C2-6 alkinil, aril, cikloalkil, heteroaril i heterocikloalkil izborno zamijenjen sa 1, 2, 3, 4 ili 5 supstituenta nezavisno odabrana od halo, C1-6 alkila, C2-6 alkenila, C2-6 alkinila, C1-6 haloalkila, halosulfanila, CN, NO2, N3, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)NRc2Rd2, NRc2C(O)ORa2, C(=NRg)NRc2Rd2, NRc2C(=NRg)NRc2Rd2, P(Rf2)2, P(ORe2)2, P(O)Re2Rf2, P(O)ORe2ORf2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, NRc2S(O)2Rb2 i S(O)2NRc2Rd2.
43.Spoj prema zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačeni time da –W’-X’-Y’-Z’ jest halo, C1-6 alkil, C2-6 alkenil, C2-6 alkinil, C1-6 haloalkil, halosulfanil, CN, NO2, N3, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)NRc2Rd2, NRc2C(O)ORa2, C(=NRg)NRc2Rd2, NRc2C(=NRg)NRc2Rd2, P(Rf2)2, P(ORe2)2, P(O)Re2Rf2, P(O)ORe2ORf2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, NRc2S(O)2Rb2 ili S(O)2NRc2Rd2.
44. Spoj prema zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačeni time da –W’-X’-Y’-Z’jest halo, C1-6 alkil, C1-6 haloalkil, CN, NO2, N3, ORa2 ili C(O)NRc2Rd2
45.Spoj prema zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačeni time da -W’-X’-Y’-Z’ jest halo, C1-6 alkil, C1-6 haloalkil, CN, NO2, N3 ili ORa2.
46.Spoj prema zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačeni time da -W’-X’-Y’-Z’ jest halo ili C(O)NRc2Rd2.
47.Spoj prema zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačeni time da imaju formulu IIa ili IIb:
48.Spoj prema zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačeni time da imaju formulu III:
49.Spoj prema zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačeni time da imaju formulu VIII:
50.Spoj prema zahtjevu 1, naznačen time da je odabran od: 2-(4-fluorofenil)-7-(4-metoksibenzil)imidazo[1,2-b] [1,2,4]triazina; 2-(4-fluorofenil)-7-[1-(4-metoksifenil)ciklopropil]imidazo[1,2-b]-[1,2,4]-triazina; 6-(1-(2-(4-fluorofenil)imidazo[1,2-b][1,2,4]triazin-7-il)ciklopropil)kinolina; 6-(4-fluorofenil)-3-(4-metoksibenzil)imidazo[1,2-a]pirimidina; 6-(4-fluorofenil)-3-(1-(4-metoksifenil)ciklopropil)imidazo[1,2-a]pirimidina; 6-(1-(6-(4-fluorofenil)imidazo[1,2-a]pirimidin-3-il)ciklopropil)kinolina; 2-fluoro-N-metil-4-[7-(kinolin-6-ilmetil)imidazo[1,2-b][1,2,4]triazin-2-il]benzamida; 2-(4-bromo-3-fluorofenil)-7-[(4-metoksifenil)tio]imidazo[1,2-b][1,2,4]triazina; 2-fluoro-4-(3-[(4-metoksifenil)tio]imidazo[1,2-a]pirimidin-6-il)-N-metilbenzamida; 2-kloro-4-3-[(4-metoksifenil)tio]imidazo[1,2-a]pirimidin-6-il-N-metilbenzamida; 2-fluoro-N-metil-4-[3-(kinolin-6-ltio)imidazo[1,2-a]pirimidin-6-il]benzamida; 2-kloro-N-metil-4-[3-(kinolin-6-iltio)imidazo[1,2-a]pirimidin-6-il]benzamida; metil-2-fluoro-4-[7-(kinolin-6-iltio)imidazo[1,2-b][1,2,4]triazin-2-il]benzoata; 2-(4-bromo-3-fluorofenil)-7-(4-metoksifenoksi)imidazo[1,2-b][1,2,4]triazina; 3-(4-metoksifenoksi)-6-(4-metil-1H-pirazol-1-il)imidazo[1,2-a]pirimidina; 6-(4-bromofenil)-3-(4-metoksifenoksi)imidazo[1,2-a]pirimidina; 2-kloro-N-metil-4-[3-(kinolin-6-iloksi)imidazo[1,2-a]pirimidin-6-il]benzamida; 2-fluoro-N-metil-4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]benzamida; 6-(4-bromofenil)-3-[(4-metoksifenil)tio]imidazo[1,2-a]pirimidina; 2-(4-fluorofenil)-7-[(4-metoksifenil)tio]imidazo[1,2-b][1,2,4]triazina; 6-(1-{6-[3-fluoro-4-(1-metil-2-okso-2-pirolidin-1-iletoksi)fenil]imidazo[1,2-a]pirimidin-3-il}ciklopropil)kinolina; 6-{1-[6-(1H-pirazol-1-il)imidazo[1,2-a]pirimidin-3-il]ciklopropil}kinolina; 6-1-[6-(4-metil-1H-pirazol-1-il)imidazo[1,2-a]pirimidin-3-il]ciklopropil}kinolina; N,N-dimetil-1-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]-1H-pirazol-4-karboksamida; N-[1-(4-metil-1,3-tiazol-2-il)etil]-1-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]-1H-pirazol-4-karboksamida; N-cikloheksil-3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-karboksamida; 3-(1-kinolin-6-ilciklopropil)-N-(tetrahidrofuran-2-ilmetil)imidazo[1,2-a]pirimidin-6-karboksamida; N-ciklobutil-4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]benzamida; 6-(1-{16-[4-(azetidin-1-ilkarbonil)fenil]imidazo[1,2-a]pirimidin-3-il}ciklopropil)kinolina; N,N-dimetil-4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]benzamida; 4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]-N-(tetrahidrofuran-2-ilmetil)benzamida; N-(1-benzilpirolidin-3-il)-N-metil-4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]benzamida; N-(1-piridin-2-ilpiperidin-4-il)-4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]benzamida; N-(1-piridin-2-iletil)-4-[3-(1-kinolin-6-ilcilopropil)imidazo[1,2-a]pirimidin-6-il]benzamida; 6-{1-[6-(4-[(3S)-3-fluoropirolidin-1-il]karbonilfenil)imidazo[1,2-a]pirimidin-3-il]ciklopropil}kinolina; N-[1-(metoksimetil)ciklobutil]-4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]benzamida; N-(1-piridin-2-ilpirolidin-3-il)-4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]benzamida; 6-[1-(6-{4-[(3-piridin-2-ilpirolidin-1-il)karbonil]fenil}imidazo[1,2-a]pirimidin-3-il)ciklopropil]kinolina; 6-{1-[6-(4-[(3S)-3-(piridin-2-iloksi)pirolidin-1-il]karbonilfenil)imidazo[1,2-a]pirimidin-3-il]ciklopropil}kinolina; N-[2-(piridin-2-iloksi)etil]-4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]benzamida; N-[1-metil-2-(piridin-2-iloksi)etil]-4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]benzamida; N-(2-fenoksietil)-4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]benzamid; N-(1S)-2,2-dimetil-1-[(metilamino)karbonil]propil-4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]benzamida; N-(1S)-1-[(dimetilamino)karbonil]-2,2-dimetilpropil-4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]benzamida; N-[(1S)-1-(azetidin-1-ilkarbonil)-2,2-dimetilpropil]-4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]benzamida; N-ciklopropil-3-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]benzamida; N-(piridin-2-ilmetil)-3-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]benzamida; N,N-dimetil-3-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]benzamida; N-metil-3-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]benzamida; N-[(1S)-1-metil-2-(metilamino)-2-oksoetil]-4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]benzamida; N-[(1R)-1-metil-2-(metilamino)-2-oksoetil]-4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]benzamida; (3R)-1-{4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]benzoil}pirolidin-3-karbonitrila; metil-4-{5-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]piridin-2-il}-piperazin-1-karboksilata; 6-[1-(6-{6-[4-(metilsulfonil)piperazin-1-il]piridin-3-il}imidazo[1,2-a]pirimidin-3-il)ciklopropil]kinolina; N,N-dimetil-4-{5-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]piridin-2-il}piperazin-1-karboksamida; N-(1S)-1-[(dimetilamino)karbonil]-2-metilpropil-4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]benzamida; N-1-[(dimetilamino)karbonil]ciklobutil-4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]benzamida; N-[(1S)-1-(azetidin-1-ilkarbonil)-2,2-dimetilpropil]-5-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]piridin-2-karboksamida; N-(1S)-2,2-dimetil-1-[(metilamino)karbonil]propil-5-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]piridin-2-karboksamida; N-(1S)-1-[(ciklopropilamino)karbonil]-2,2-dimetilpropil-5-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]piridin-2-karboksamida; N-[(1S)-2-(dimetilamino)-1-metil-2-oksoetil]-5-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]piridin-2-karboksamida; N-[(1R)-2-(dimetilamino)-1-metil-2-oksoetil]-5-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]piridin-2-karboksamida; 6-(1-{6-[4-(2-okso-2-pirolidin-1-iletoksi)fenil]imidazo[1,2-a]pirimidin-3-il}ciklopropil)kinolina; 1-{4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]fenil}ciklopropankarbonitrila; N,N-dimetil-4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]benzensulfonamida; metil-2-fluoro-4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]benzilkarbamata; N’-2-fluoro-4[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]benzil-N,N-dimetiluree; (3R)-1-{2-fluoro-4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]benzil}pirolidin-3-ola; 6-(1-{6-[3-fluoro-4-(1H-pirazol-1-ilmetil)fenil]imidazo[1,2-a]pirimidin-3-il}ciklopropil)kinolina; 3-{2-fluoro-4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]benzil}-1,3-oksazolidin-2-ona; 2-fluoro-N-metil-4-[7-(kinoksalin-6-ilmetil)imidazo[1,2-b][1,2,4]triazin-2-il]benzamida; 6-{1-[6-(4-kloro-1H-pirazol-1-il)imidazo[1,2-a]pirimidin-3-il]ciklopropil}kinolina; 6-{1-[6-(2-metil-1,3-tiazol-4-il)imidazo[1,2-a]pirimidin-3-il]ciklopropil} kinolina; 6-{1-[6-(1,3-tiazol-4-il)imidazo[1,2-a]pirimidin-3-il]ciklopropil}kinolina; 3-fluoro-N-metil-4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]benzamida; (3S)-1-{3-fluoro-4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]benzoil}pirolidin-3-ola; 2,5-difluoro-N-metil-4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]benzamida; 2,5-difluoro-4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]benzamida; N-ciklopropil-2,5-difluoro-4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]benzamida; 2,5-difluoro-N-(trans-4-hidroksicikloheksil)-4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]benzamida; 1-{2-fluoro-4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]fenil}pirolidin-2-ona; 3-{2-fluoro-4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]fenil}-1,3-oksazolidin-2-ona; etil-4-{4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]-1H-pirazol-1-il}piperidin-1-karboksilata; 2-(4-{2-fluoro-4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]fenil}-1H-pirazol-1-il)-N,N-dimetilacetamida; 5-{2-fluoro-4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]fenil}-N-metilpiridin-2-karboksamida; 5-{2-fluoro-4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]fenil}-N,N-dimetilpiridin-2-karboksamida; 6-(1-{6-[3-fluoro-4-(1-metil-1H-pirazol-4-il)fenil]imidazo[1,2-a]pirimidin-3-il}ciklopropil)kinolina; 6-(1-{6-[1-(fetrahidrofuran-3-il)-1H-pirazol-4-il]imidazo[1,2-a]pirimidin-3-il}ciklopropil)kinolina; 6-(1-{6-[1-(1-benzilpirolidin-3-il)-1H-pirazol-4-il]imidazo[1,2-a]pirimidin-3-il}ciklopropil)kinolina; 6-{1-[6-(1-metil-1H-pirazol-4-il)imidazo[1,2-a]pirimidin-3-il]ciklopropil}kinolina; N,N-dimetil-4-{4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]-1H-pirazol-1-il}piperidin1-karboksamida; 4-{4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]-1H-pirazol-1-il}cikloheksanola; {4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]-1H-pirazol-1-il} acetonitrila; N-metil-5-{4-[7-(1-kinolin-6-ilciklopropil)imidazo[1,2-b][1,2,4]triazin-2-il]fenil}piridin-2-karboksamida; 6-{1-[2-(4-pirimidin-5-il-fenil)imidazo[1,2-b][1,2,4]triazin-7-il]ciklopropil}kinolina; 6-(1-{2-[4-(1-acetil-1,2,3,6-tetrahidropiridin-4-il)fenil]imidazo[1,2-b][1,2,4]triazin-7-il}ciklopropil)kinolina; 6-[1-(2-(4-[1-(metilsulfonil)-1,2,3,6-tetrahidropiridin-4-il]fenil}imidazo[1,2-b][1,2,4]triazin-7-il)ciklopropil]kinolina; N,N-dimetil-5-{4-[7-(1-kinolin-6-ilciklopropil)imidazo[1,2-b][1,2,4]triazin-2-il]fenil}piridin-2-karboksamida; 6-(1-{2-[4-(1H-imidazol-1-il)fenil]imidazo[1,2-b][1,2,4]triazin-7-il}ciklopropil)-kinolina; 2-fluoro-N-(trans-4-hidroksicikloheksil)-4-[7-(1-kinolin-6-ilciklopropil)imidazo[1,2-b][1,2,4]triazin-2-il]benzamida; N-ciklopropil-2-fluoro-4-[7-(1-kinolin-6-ilciklopropil)imidazo[1,2-b][1,2,4]triazin-2-il]benzamida; 2-fluoro-N-metil-4-[7-(1-kinolin-6-ilciklopropil)imidazo[1,2-b][1,2,4]triazin-2-il]benzamida; 2-fluoro-N-[1-(metoksimetil)ciklopropil]-4-[7-(1-kinolin-6-ilciklopropil)imidazo[1,2-b][1,2,4]triazin-2-il]benzamida; 2-fluoro-4-(7-(1-(kinolin-6-il)ciklopropil)imidazo[1,2-b][1,2,4]triazin-2-il)benzamida; 4-[7-(1-kinolin-6-ilciklopropil)imidazo[1,2-b][1,2,4]triazin-2-il]-N-(tetrahidrofuran-2-ilmetil)benzamida; N-(piridin-2-ilmetil)-4-[7-(1-kinolin-6-ilciklopropil)imidazo[1,2-b][1,2,4]triazin-2-il]benzamida; N-ciklopropil-4-[7-(1-kinolin-6-ilciklopropil)imidazo[1,2-b][1,2,4]triazin-2-il]benzamida; N-ciklobutil-4-[7-(1-kinolin-6-ilciklopropil)imidazo[1,2-b][1,2,4]triazin-2-il]benzamida; N-(1-piridin-2-ilciklopropil)-4-[7-(1-kinolin-6-ilciklopropil)imidazo[1,2-b][1,2,4]triazin-2-il]benzamida; N-(2-hidroksi-1,1-dimetiletil)-4-[7-(1-kinolin-6-ilciklopropil)imidazo[1,2-b][1,2,4]triazin-2-il]benzamida; N-[(1S)-1-benzil-2-hidroksietil]-4-[7-(1-kinolin-6-ilciklopropil)imidazo[1,2-b][1,2,4]triazin-2-il]benzamida; (3R)-1-{4-[7-(1-kinolin-6-ilciklopropil)imidazo[1,2-b][1,2,4]triazin-2-il]benzoil}pirolidin-3-ola; 4-(7-(1-(kinolin-6-il)ciklopropil)imidazo[1,2-b][1,2,4]triazin-2-il)-N-(tetrahidro-2H-piran-4-il)benzamida; N-ciklopropil-N-metil-4-[7-(1-kinolin-6-ilciklopropil)imidazo[1,2-b][1,2,4]triazin-2-il]benzamida; N-[1-(metoksimetil)ciklopropil]-4-[7-(1-kinolin-6-ilciklopropil)imidazo[1,2-b][1,2,4]triazin-2-il]benzamida; N-[1-(metoksimetil)ciklobutil]-4-[7-(1-kinolin-6-ilciklopropil)imidazo[1,2-b][1,2,4]triazin-2-il]benzamida; N-[(1S)-1-(metoksimetil)-2-metilpropil]-4-[7-(1-kinolin-6-ilciklopropil)imidazo[1,2-b][1,2,4]triazin-2-il]benzamida; N-[4-(metoksimetil)tetrahidro-2H-piran-4-il]-4-[7-(1-kinolin-6-ilciklopropil)imidazo[1,2-b][1,2,4]triazin-2-il]benzamida; 4-[7-(1-kinolin-6-ilciklopropil)imidazo[1,2-b][1,2,4]triazin-2-il]-N-1,3-tiazol-2-ilbenzamida; N-pirimidin-4-il-4-[7-(1-kinolin-6-ilciklopropil)imidazo[1,2-b][1,2,4]triazin-2-il]benzamida; N-[4-(metoksimetil)tetrahidro-2H-piran-4-il]-4-[7-(1-kinolin-6-ilciklopropil)imidazo[1,2-b][1,2,4]triazin-2-il]benzamida; N-ciklopropil-2-fluoro-4-[7-(kinolin-6-ilmetil)imidazo[1,2-b][1,2,4]triazin-2-il]benzamida; 2-fluoro-N-[1-(metoksimetil)ciklopropil]-4-[7-(kinolin-6-ilmetil)imidazo[1,2-b][1,2,4]triazin-2-il]benzamida; 2-fluoro-4-[7-(kinolin-6-ilmetil)imidazo[1,2-b][1,2,4]triazin-2-il]-N-(tetrahidro-2H-piran-4-il)benzamida; (3R)-1-{2-fluoro-4-[7-(kinolin-6-ilmetil)imidazo[1,2-b][1,2,4]triazin-2-il]benzoil}pirolidin-3-ola; 2-fluoro-4-[7-(kinolin-6-ilmetil)imidazo[1,2-b][1,2,4]triazin-2-il]benzamida; 2-fluoro-N-(trans-4-hidroksicikloheksil)-4-[7-(kinolin-6-ilmetil)imidazo[1,2-b][1,2,4]triazin-2-il]benzamida; 6-{2-[3-fluoro-4-(1H-imidazol-1-il)fenil]imidazo[1,2-b][1,2,4]triazin-7-ilmetil}kinolina; 3-{2-fluoro-4-[7-(kinolin-6-ilmetil)imidazo[1,2-b][1,2,4]triazin-2-il]fenil}-1,3-oksazolidin-2-ona; N-(1S)-2,2-dimetil-1-[(metilamino)karbonil]propil-2-fluoro-4-[7-(kinolin-6-ilmetil)imidazo[1,2-b][1,2,4]triazin-2-il]benzamida; N-(1S)-1-[(dimetilamino)karbonil]-2,2-dimetilpropil-2-fluoro-4-[7-(kinolin-6-ilmetil)imidazo[1,2-b] [1,2,4]triazin-2-il]benzamida; N-[(1S)-1-(azetidin-1-ilkarbonil)-2,2-dimetilpropil]-2-fluoro-4-[7-(kinolin-6-ilmetil)imidazo[1,2-b][1,2,4]triazin-2-il]benzamida; N-{(1S)-1-[(dimetilamino)karbonil]-3-metilbutil-2-fluoro-4-[7-(kinolin-6-ilmetil)imidazo[1,2-b][1,2,4]triazin-2-il]benzamida; 2-fluoro-N-{(1R)-3-metil-1-[(metilamino)karbonil]butil}-4-[7-(kinolin-6-ilmetil)imidazo[1,2-b][1,2,4]triazin-2-il]benzamida; N-{(1R)-1-[(dimetilamino)karbonil]-3-metilbutil}-2-fluoro-4-[7-(kinolin-6-ilmetil)imidazo[1,2-b][1,2,4]triazin-2-il]benzamida; N-[(1R)-1-(azetidin-1-ilkarbonil)-3-metilbutil]-2-fluoro-4-[7-(kinolin-6-ilmetil)imidazo[1,2-b][1,2,4] triazin-2-il]benzamida; 3-{4-[7-(kinolin-6-ilmetil)imidazo[1,2-b][1,2,4]triazin-2-il]-1H-pirazol-1-il} propanenitrila; 4-[7-(kinolin-6-ilmetil)imidazo[1,2-b][1,2,4]triazin-2-il]-1H-pirazol-1-ilacetonitrila; 2-{4-[7-(kinolin-6-ilmetil)imidazo[1,2-b][1,2,4]triazin-2-il]-1H-pirazol-1-il}acetamida; metil-4-{4-[7-(kinolin-6-ilmetil)imidazo[1,2-b][1,2,4]triazin-2-il]-1H-pirazol-1-il}piperidin-1-karboksilata; 2-fluoro-N-[(1S,2S)-2-hidroksiciklopentil]-4-[7-(kinolin-6-ilmetil)imidazo[1,2-b][1,2,4]triazin-2-il]benzamida; 2-fluoro-N-(2-hidroksietil)-4-[7-(kinolin-6-ilmetil)imidazo[1,2-b][1,2,4]triazin-2-il]benzamida; 2-fluoro-N-[1-(metoksimetil)ciklobutil]-4-[7-(kinolin-6-ilmetil)imidazo[1,2-b][1,2,4]triazin-2-il]benzamida; 2-fluoro-N-[4-(metoksimetil)tetrahidro-2H-piran-4-il]-4-[7-(kinolin-6-ilmetil)imidazo[1,2-b][1,2,4]triazin-2-il]benzamida; N-(ciklopropilmetil)-2-fluoro-4-[7-(kinolin-6-ilmetil)imidazo[1,2-b][1,2,4]triazin-2-il]benzamida; 2-fluoro-4-[7-(kinolin-6-ilmetil)imidazo[1,2-b][1,2,4]triazin-2-il]-N-(tetrahidro-2H-piran-4-ilmetil)benzamida; N-[2-(dimetilamino)etil]-2-fluoro-4-[7-(kinolin-6-ilmetil)imidazo[1,2-b][1,2,4]triazin-2-il]benzamida; 2-fluoro-N-(2-piperidin-1-iletil)-4-[7-(kinolin-6-ilmetil)imidazo[1,2-b][1,2,4]triazin-2-il]benzamida; 2-fluoro-N-[2-(1-metilpirolidin-2-il)etil]-4-[7-(kinolin-6-ilmetil)imidazo[1,2-b][1,2,4]triazin-2-il]benzamida; 2-fluoro-N-(piridin-2-ilmetil)-4-[7-(kinolin-6-ilmetil)imidazo[1,2-b][1,2,4]triazin-2-il]benzamida; 2-fluoro-N-(piridin-3-ilmetil)-4-[7-(kinolin-6-ilmetil)imidazo[1,2-b][1,2,4]triazin-2-il]benzamida; 2-fluoro-N-(piridin-4-ilmetil)-4-[7-(kinolin-6-ilmetil)imidazo[1,2-b][1,2,4]triazin-2-il]benzamida; 2-fluoro-N-(2-piridin-2-iletil)-4-[7-(kinolin-6-ilmetil)imidazo[1,2-b] [1,2,4]triazin-2-il]benzamida; 2-fluoro-N-(1-piridin-3-iletil)-4-[7-(kinolin-6-ilmetil)imidazo[1,2-b][1,2,4]triazin-2-il]benzamida; 2-fluoro-N-(1-piridin-4-iletil)-4-[7-(kinolin-6-ilmetil)imidazo[1,2-b][1,2,4]triazin-2-il]benzamida; 2-fluoro-N-[(1S)-1-(hidroksimetil)-2,2-dimetilpropil]-4-[7-(kinolin-6-ilmetil)imidazo[1,2-b][1,2,4]triazin-2-il]benzamida; 2-fluoro-N-[1-(hidroksimetil)ciklopentil]-4-[7-(kinolin-6-ilmetil)imidazo[1,2-b][1,2,4]triazin-2-il]benzamida; 2-fluoro-N-(2-metoksi-1-metiletil)-4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]benzamida; 6-{1-[6-(3-fluoro-4-[(3S)-3-fluoropirolidin-1-il]karbonilfenil)imidazo[1,2-a]pirimidin-3-il]ciklopropil} kinolina; 2-fluoro-N-(piridin-2-ilmetil)-4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]benzamida; 2-fluoro-N-(1-piridin-2-ilciklopropil)-4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]benzamida; 2-fluoro-N-(1-piridin-2-ilpirolidin-3-il)-4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]benzamida; 2-fluoro-4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]-N-[(3R)-tetrahidrofuran-3-il]benzamida; 2-fluoro-4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]-N-(tetrahidrofuran-2-ilmetil)benzamida; N-ciklopropil-2-fluoro-4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]benzamida; 2-fluoro-N-[(1S)-1-(metoksimetil)-2-metilpropil]-4-[3-(1-kinolin-6-ilcklopropil)imidazo[1,2-a]pirimidin-6-il]benzamida; 2-fluoro-4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]benzamida; 2-fluoro-N-metil-N-2-[metil(piridin-2-il)amino]etil-4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]benzamida; 2-kloro-N-metil-4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]benzamida; 2-kloro-N-ciklopropil-4[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]benzamida; 2-kloro-4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]-N-(tetrahidrofuran-3-il)benzamida; 2-kloro-N-(1-piridin-2-iletil)-4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]benzamida; 6-(1-{6-[4-(Azetidin-1-ilkarbonil)-3-klorofenil]imidazo[1,2-a]pirimidin-3-il}ciklopropil)kinolina; 2-kloro-N-(1-piridin-2-ilpirolidin-3-il)-4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]benzamida; 2-kloro-N-[1-metil-2-(piridin-2-iloksi)etil]-4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]benzamida; 2-kloro-N-(1S)-1-[(dimetilamino)karbonil]-2-metilpropil-4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]benzamida; 2-ciklopropil-5-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]izoindolin-1-ona; 2-etil-5-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]izoindolin-1-ona; 2-(2-metoksi-1-metiletil)-S-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]izoindolin-1 -ona; 2-(piridin-2-ilmetil)-5-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]izoindolin-1-ona; 2-metil-5-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]izoindolin-1-ona; N-etil-1-{4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]fenil}ciklopropankarboksamida; N-(1-piridin-2-iletil)-1-{4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]fenil}ciklopropankarboksamida; N-[1-metil-2-(piridin-2-iloksi)etil]-1-{4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]fenil}ciklopropankarboksamida; 2-{2-fluoro-4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]fenil}-2-hidroksi-N-metilacetamida; 2-{2-fluoro-4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]fenil}-2-hidroksi-N,N-dimetilacetamida; N-(3-[2-(4-bromo-3-fluorofenil)imidazo[1,2-b][1,2,4]triazin-7-il]metilfenil)-N’-etiluree; 2-(2,3-dihlorofenil)-7-(1-kinolin-6-ilciklopropil)imidazo[1,2-b][1,2,4]triazin-3-amina; 2,3-difluoro-N-metil-4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]benzamida; 6-difluoro-N-metil-4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]benzamida; 2-fluoro-N-metil-4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]benzensulfonamida; N,N-dimetil-2-{3-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]-1H-pirazol-1-il}acetamida; N-[(1S)-1-(azetidin-1-ilkarbonil)-2,2-dimetilpropil]-2-fluoro-4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]benzamida; N-[2-(dimetilamino)-1-metil-2-oksoetil]-2-fluoro-4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]benzamida; N-(2-azetidin-1-il-1-metil-2-oksoetil)-2-fluoro-4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]benzamida; 2-fluoro-N-2-[(3R)-3-metoksipirolidin-1-il]-1-metil-2-oksoetil-4-[3-(1-kinolin-6-ilciklopropil)imidazo[1,2-a]pirimidin-6-il]benzamida; 2-fluoro-N-[(1-hidroksiciklopropil)metil]-4-[7-(kinolin-6-ilmetil)imidazo[1,2-b][1,2,4]triazin-2-il]benzamida; metil-4-(cijanometil)-4-{4-[7-(kinolin-6-ilmetil)imidazo[1,2-b][1,2,4]triazin-2-il]-1H-pirazol-1-il}piperidin-1-karboksilata; etil-4-(cijanometil)-4-{4-[7-(kinolin-6-ilmetil)imidazo[1,2-b][1,2,4]triazin-2-il]-1H-pirazol-1-il}piperidin-1-karboksilata; (1-acetil-4-{4-[7-(kinolin-6-ilmetil)imidazo[1,2-b] [1,2,4]triazin-2-il]-1H-pirazol-1-il}piperidin-4-il)acetonitrila, ili njihovih farmaceutski prihvatljivih soli.
51.Spoj prema zahtjevu 1, naznačen time da je 2-fluoro-N-metil-4-[7-(kinolin-6-ilmetil)imidazo[1,2-b][1,2,4]triazin-2-il]benzamid ili njegova farmaceutski prihvatljiva sol.
52.Sastav, naznačen time da sadrži spoj bilo kojeg zahtjeva od 1 do 51 ili njegovu farmaceutski prihvatljivu sol i najmanje jedan farmaceutski prihvatljivi nosač.
53.Sastav, naznačen time da sadrži spoj prema zahtjevu 51 ili njegovu farmaceutski prihvatljivu sol i najmanje jedan farmaceutski prihvatljivi nosač.
54.Metoda inhibiranja aktivnosti receptorske ili nereceptorske tirozin-kinaze ex vivo, naznačena time da uključuje dovođenje navedene kinaze u kontakt sa spojem iz bilo kojeg zahtjeva od 1 do 51 ili njegovom farmaceutski prihvatljivom soli.
55.Metoda prema zahtjevu 54, naznačena time da navedena kinaza pripada podfamiliji Met, PDGFR, HER, FLK, Src, Abl ili Jak.
56.Metoda prema zahtjevu 54, naznačena time da je navedena kinaza c-Met, Ron, PDGFR beta, c-kit, EGFR, HER2, KDR, flt-3, Src, Abl, Jak1, Jak2 ili Jak 3 kinaza.
57.Metoda prema zahtjevu 54, naznačena time da je navedena kinaza c-Met.
58.Metoda inhibiranja signalnog puta HGF/c-Met kinaze u stanici ex vivo, naznačena time da uključuje dovođenje navedene stanice u kontakt sa spojem iz bilo kojeg zahtjeva od 1 do 51 ili njegovom farmaceutski prihvatljivom soli.
59.Metoda inhibiranja proliferativne aktivnosti stanice ex vivo, naznačena time da uključuje dovođenje navedene stanice u kontakt sa spojem iz bilo kojeg zahtjeva od 1 do 51 ili njegovom farmaceutski prihvatljivom soli.
60.Spoj prema bilo kojem zahtjevu od 1 do 51 ili njegova farmaceutski prihvatljiva sol, naznačeni time da se upotrebljavaju u inhibiciji rasta tumora kod pacijenata.
61.Spoj prema bilo kojem zahtjevu od 1 do 51 ili njegova farmaceutski prihvatljiva sol, naznačeni time da se upotrebljavaju u inhibiciji metastaze tumora kod pacijenata.
62.Spoj prema bilo kojem zahtjevu od 1 do 51 ili njegova farmaceutski prihvatljiva sol, naznačeni time da se upotrebljavaju u liječenju bolesti kod pacijenta, gdje je navedena bolest povezana s nepravilnom regulacijom signalnog puta HGF/c-MET.
63.Spoj ili njegova farmaceutski prihvatljiva sol prema zahtjevu 62, naznačeni time da se upotrebljavaju u liječenju bolesti pri čemu je navedena bolest rak, ateroskleroza, plućna fibroza, renalna fibroza i regeneracija, bolest jetre, alergijski poremećaj, upalna bolest, autoimuni poremećaj, cerebrovaskularna bolest, kardiovaskularna bolest ili stanje povezano sa transplantacijom organa.
64.Spoj prema bilo kojem zahtjevu od 1 do 51 ili njegova farmaceutski prihvatljiva sol, naznačeni time da se upotrebljavaju u liječenju raka kod pacijenta.
65.Spoj ili njegova farmaceutski prihvatljiva sol prema zahtjevu 64, naznačeni time da se upotrebljavaju u liječenju raka pri čemu je navedeni rak karcinom, mišićnokoštani sarkom, sarkom mekog tkiva ili hematopoetski malignitet.
66.Spoj ili njegova farmaceutski prihvatljiva sol prema zahtjevu 64, naznačeni time da se upotrebljavaju u liječenju raka pri čemu je navedeni rak rak mokraćnog mjehura, rak dojke, rak grlića materice, kolangiokarcinom, rak debelog crijeva, rak jednjaka, rak želuca, rak glave i vrata, rak bubrega, rak jetre, rak pluća, nazofaringealni rak, rak jajnika, rak pankreasa, rak prostate, rak štitne žlijezde, osteosarkom, sinovijalni sarkom, rabdomiosarkom, MFH/fibrosarkom, leiomiosarkom, Kaposijev sarkom, multipli mijelom, limfom, leukemija odraslih T stanica, akutna mijelogena leukemija, kronična mijeloična leukemija, glioblastom, astrocitom, melanom, mezoteliom ili Wilmsov tumor. 1
MEP-2013-35A 2006-11-22 2007-11-19 Imidazotriazini i imidazopirimidini kao inhibitori kinaze ME01507B (me)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US86084006P 2006-11-22 2006-11-22
US86145906P 2006-11-29 2006-11-29
US95723607P 2007-08-22 2007-08-22
PCT/US2007/085100 WO2008064157A1 (en) 2006-11-22 2007-11-19 Imidazotriazines and imidazopyrimidines as kinase inhibitors
EP07864592A EP2099447B1 (en) 2006-11-22 2007-11-19 Imidazotriazines and imidazopyrimidines as kinase inhibitors

Publications (1)

Publication Number Publication Date
ME01507B true ME01507B (me) 2014-04-20

Family

ID=39166437

Family Applications (2)

Application Number Title Priority Date Filing Date
MEP-2016-13A ME02372B (me) 2006-11-22 2007-11-19 Imidazotriazini i imidazopiramidini kao inhibitori kinaze
MEP-2013-35A ME01507B (me) 2006-11-22 2007-11-19 Imidazotriazini i imidazopirimidini kao inhibitori kinaze

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MEP-2016-13A ME02372B (me) 2006-11-22 2007-11-19 Imidazotriazini i imidazopiramidini kao inhibitori kinaze

Country Status (35)

Country Link
US (8) US7767675B2 (me)
EP (4) EP2497470B8 (me)
JP (1) JP5572388B2 (me)
KR (2) KR101532256B1 (me)
CN (2) CN103288833B (me)
AR (1) AR066142A1 (me)
AU (1) AU2007323725B2 (me)
CA (1) CA2669991C (me)
CL (1) CL2007003341A1 (me)
CO (1) CO6210810A2 (me)
CR (1) CR10841A (me)
CY (4) CY1116763T1 (me)
DK (3) DK3034075T3 (me)
EA (2) EA032254B1 (me)
EC (1) ECSP099400A (me)
ES (3) ES2398843T3 (me)
FR (1) FR22C1060I2 (me)
GE (1) GEP20125658B (me)
HR (3) HRP20130106T1 (me)
HU (2) HUE026659T2 (me)
IL (4) IL198716A (me)
LT (2) LT3034075T (me)
LU (1) LUC00293I2 (me)
ME (2) ME02372B (me)
MX (1) MX2009005144A (me)
MY (2) MY188335A (me)
NL (1) NL301209I2 (me)
NO (4) NO346024B1 (me)
NZ (1) NZ577127A (me)
PL (3) PL3034075T3 (me)
PT (3) PT2497470E (me)
RS (3) RS57741B1 (me)
SI (3) SI3034075T1 (me)
TW (1) TWI429432B (me)
WO (1) WO2008064157A1 (me)

Families Citing this family (147)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2455382B1 (en) 2005-12-13 2016-10-26 Incyte Holdings Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
MX2008013238A (es) 2006-04-12 2008-10-21 Merck & Co Inc Antagonistas de los canales de calcio de tipo t de piridil amida.
US7683060B2 (en) * 2006-08-07 2010-03-23 Incyte Corporation Triazolotriazines as kinase inhibitors
ME02372B (me) 2006-11-22 2016-06-20 Incyte Holdings Corp Imidazotriazini i imidazopiramidini kao inhibitori kinaze
EP3070090B1 (en) 2007-06-13 2018-12-12 Incyte Holdings Corporation Use of salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h- pyrazol-1-yl)-3- cyclopentylpropanenitrile
CN101910133A (zh) * 2007-10-24 2010-12-08 默沙东公司 杂环苯基酰胺t-型钙通道拮抗剂
PE20091468A1 (es) 2008-02-28 2009-10-22 Novartis Ag DERIVADOS DE 3-METIL-IMIDAZO-[1,2-b]-PIRIDAZINA
WO2009143211A2 (en) * 2008-05-21 2009-11-26 Incyte Corporation Salts of 2-fluoro-n-methyl-4-[7-(quinolin-6-yl-methyl)- imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same
US20110269740A1 (en) * 2008-07-02 2011-11-03 Ambit Biosciences Corporation Jak kinase modulating compounds and methods of use thereof
FR2933982A1 (fr) * 2008-07-18 2010-01-22 Sanofi Aventis Nouveaux derives imidazo°1,2-a!pyrimidine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de met
UY32049A (es) * 2008-08-14 2010-03-26 Takeda Pharmaceutical Inhibidores de cmet
CA3121743A1 (en) 2009-01-15 2010-07-22 Incyte Holdings Corporation Processes for preparing jak inhibitors and related intermediate compounds
AU2010213192A1 (en) * 2009-02-13 2011-08-04 Bayer Intellectual Property Gmbh Fused pyrimidines
SG176111A1 (en) 2009-05-22 2011-12-29 Incyte Corp 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
JP5775070B2 (ja) 2009-05-22 2015-09-09 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ ヤヌスキナーゼ阻害剤としてのピラゾール−４−イル−ピロロ［２，３−ｄ］ピリミジンおよびピロール−３−イル−ピロロ［２，３−ｄ］ピリミジンのＮ−（ヘテロ）アリール−ピロリジン誘導体
CN104945420A (zh) 2009-06-29 2015-09-30 因塞特公司 作为pi3k抑制剂的嘧啶酮类
JP5781510B2 (ja) 2009-08-12 2015-09-24 ノバルティス アーゲー ヘテロ環式ヒドラゾン化合物および癌および炎症の処置のためのそれらの使用
JP5775871B2 (ja) 2009-08-20 2015-09-09 ノバルティス アーゲー ヘテロ環式オキシム化合物
AR078012A1 (es) 2009-09-01 2011-10-05 Incyte Corp Derivados heterociclicos de las pirazol-4-il- pirrolo (2,3-d) pirimidinas como inhibidores de la quinasa janus
WO2011075643A1 (en) 2009-12-18 2011-06-23 Incyte Corporation Substituted heteroaryl fused derivatives as pi3k inhibitors
EP3795573B1 (en) 2009-12-31 2022-07-06 Hutchison Medipharma Limited Certain triazolopyrazines, compositions thereof and methods of use therefor
EA025304B1 (ru) 2010-02-03 2016-12-30 Инсайт Холдингс Корпорейшн ИМИДАЗО[1,2-b][1,2,4]ТРИАЗИНЫ В КАЧЕСТВЕ c-Met ИНГИБИТОРОВ
PT3354652T (pt) 2010-03-10 2020-07-20 Incyte Holdings Corp Derivados de piperidin-4-ilazetidina como inibidores de jak1
US8518945B2 (en) * 2010-03-22 2013-08-27 Hoffmann-La Roche Inc. Pyrrolopyrazine kinase inhibitors
US8410117B2 (en) * 2010-03-26 2013-04-02 Hoffmann-La Roche Inc. Imidazopyrimidine derivatives
AR081823A1 (es) 2010-04-14 2012-10-24 Incyte Corp DERIVADOS FUSIONADOS COMO INHIBIDORES DE PI3Kd
KR20130094710A (ko) 2010-04-14 2013-08-26 어레이 바이오파마 인크. Ｊａｋ 키나아제의 억제제로서 5,7-치환된-이미다조［1,2-ｃ］피리미딘
JP5960688B2 (ja) 2010-05-17 2016-08-02 インコゼン セラピューティクス プライベート リミテッド プロテインキナーゼ調節物質としての新規３，５−二置換−３ｈ−［１，２，３］トリアゾロ［４，５−ｂ］ピリジン化合物
RS54824B1 (sr) 2010-05-21 2016-10-31 Incyte Holdings Corp Topikalna formulacija za inhibiciju jak-a
WO2012068440A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
CA2818542A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
EP2655374B1 (en) 2010-12-20 2019-10-23 Incyte Holdings Corporation N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors
US9000186B2 (en) 2011-02-01 2015-04-07 Kyowa Hakko Kirin Co., Ltd. Ring-fused heterocyclic derivative
US9108984B2 (en) 2011-03-14 2015-08-18 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
WO2012135009A1 (en) 2011-03-25 2012-10-04 Incyte Corporation Pyrimidine-4,6-diamine derivatives as pi3k inhibitors
MY165963A (en) 2011-06-20 2018-05-18 Incyte Holdings Corp Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
US8883819B2 (en) 2011-09-01 2014-11-11 Irm Llc Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
KR102507287B1 (ko) 2011-09-02 2023-03-07 인사이트 홀딩스 코포레이션 Ｐｉ３ｋ 억제제로서 헤테로시클릴아민
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
EA026655B1 (ru) 2011-09-15 2017-05-31 Новартис Аг 6-ЗАМЕЩЕННЫЕ 3-(ХИНОЛИН-6-ИЛТИО)[1,2,4]ТРИАЗОЛО[4,3-a]ПИРИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ c-MET ТИРОЗИНКИНАЗЫ
CN103030654A (zh) * 2011-10-09 2013-04-10 济南赛文医药技术有限公司 一种小分子c-Met蛋白激酶抑制剂
US20140228349A1 (en) * 2011-10-12 2014-08-14 Array Biopharma Inc. 5,7-substituted-imidazo[1,2-c]pyrimidines
EP4556010A3 (en) 2011-11-30 2025-07-23 Emory University Jak inhibitors for use in the prevention or treatment of a viral disease caused by a coronaviridae
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
JP2015512425A (ja) * 2012-04-03 2015-04-27 ノバルティス アーゲー チロシンキナーゼ阻害剤との組合せ製品及びそれらの使用
MX2014011987A (es) 2012-04-03 2014-11-10 Novartis Ag Combinaciones de inhibidores de cinasa de tirosina y su uso.
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
ES2704744T3 (es) 2012-06-13 2019-03-19 Incyte Holdings Corp Compuestos tricíclicos sustituidos como inhibidores de FGFR
HK1211476A1 (en) * 2012-08-16 2016-05-27 Novartis Ag Combination of pi3k inhibitor and c-met inhibitor
CN113384546A (zh) 2012-11-15 2021-09-14 因赛特公司 鲁索利替尼的缓释剂型
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
WO2014138168A1 (en) 2013-03-06 2014-09-12 Incyte Corporation Processes and intermediates for making a jak inhibitor
CN104109166B (zh) * 2013-04-17 2017-06-20 上海医药集团股份有限公司 喹啉类化合物、其制备方法、中间体、药物组合物和应用
WO2014174478A1 (en) 2013-04-26 2014-10-30 Novartis Ag Pharmaceutical combinations of a pkc inhibitor and a c-met receptor tyrosine kinase inhibitor
SG10201801069QA (en) 2013-08-07 2018-03-28 Incyte Corp Sustained release dosage forms for a jak1 inhibitor
US10570204B2 (en) 2013-09-26 2020-02-25 The Medical College Of Wisconsin, Inc. Methods for treating hematologic cancers
GB201321732D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321736D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
SG10201900002QA (en) 2014-01-24 2019-02-27 Dana Farber Cancer Institue Inc Antibody molecules to pd-1 and uses thereof
EP3099717B1 (en) 2014-01-31 2019-03-27 Novartis AG Antibody molecules to tim-3 and uses thereof
SI3105218T1 (sl) 2014-02-13 2019-11-29 Incyte Corp Ciklopropilamini kot inhibitorji LSD1
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
EP3105219B9 (en) 2014-02-13 2018-10-03 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
MX373103B (es) 2014-02-13 2020-04-17 Incyte Holdings Corp Ciclopropilaminas como inhibidores de desmetilasa específica de lisina 1 (lsd1).
US20150259420A1 (en) 2014-03-14 2015-09-17 Novartis Ag Antibody molecules to lag-3 and uses thereof
JP6752715B2 (ja) 2014-03-26 2020-09-09 アステックス、セラピューティックス、リミテッドＡｓｔｅｘ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ 組合せ
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
WO2015191677A1 (en) 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
WO2016007727A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
TW201613925A (en) 2014-07-10 2016-04-16 Incyte Corp Imidazopyrazines as LSD1 inhibitors
TWI687419B (zh) 2014-07-10 2020-03-11 美商英塞特公司 作為ｌｓｄ１抑制劑之咪唑并吡啶及咪唑并吡嗪
WO2016011658A1 (en) * 2014-07-25 2016-01-28 Novartis Ag Combination therapy
US10085993B2 (en) * 2014-07-25 2018-10-02 Novartis Ag Tablet formulation of 2-fluoro-N-methyl-4-[ 7-( quinolin-6-ylmethyl) imidazo [1,2-B] [1,2,4] triazin-2-yl] benzamide
ES2831416T3 (es) * 2014-07-31 2021-06-08 Novartis Ag Terapia de combinación de un inhibidor de MET y un inhibidor de EGFR
ES2771926T3 (es) 2014-09-13 2020-07-07 Novartis Ag Terapias de combinación
AU2015327868A1 (en) 2014-10-03 2017-04-20 Novartis Ag Combination therapies
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
TWI716362B (zh) 2014-10-14 2021-01-21 瑞士商諾華公司 針對ｐｄ－ｌ１之抗體分子及其用途
MX373169B (es) * 2015-02-20 2020-04-24 Incyte Holdings Corp Heterociclos bicíclicos como inhibidores de receptores del factor de crecimiento fibroblástico (fgfr).
TWI713497B (zh) * 2015-02-26 2020-12-21 南韓商愛思開生物製藥股份有限公司 咪唑并嘧啶及咪唑并三衍生物及包含該衍生物之醫藥組成物
SI3831833T1 (sl) 2015-02-27 2023-03-31 Incyte Holdings Corporation Postopki za pripravo inhibitorja PI3K
HK1248603A1 (zh) 2015-03-10 2018-10-19 Aduro Biotech, Inc. 用於活化"干扰素基因的刺激剂"依懒性信号传导的组合物和方法
EP3277689B1 (en) 2015-04-03 2019-09-04 Incyte Corporation Heterocyclic compounds as lsd1 inhibitors
JP6801159B2 (ja) 2015-04-21 2020-12-16 ジエンス ヘンルイ メデイシンカンパニー リミテッドＪｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．，Ｌｔｄ． イミダゾイソインドール誘導体、その製造方法及びその医薬用途
US9732097B2 (en) 2015-05-11 2017-08-15 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
US9988401B2 (en) 2015-05-11 2018-06-05 Incyte Corporation Crystalline forms of a PI3K inhibitor
JP6507267B2 (ja) 2015-05-22 2019-04-24 チョン クン ダン ファーマシューティカル コーポレーション 選択的ヒストンデアセチラーゼ阻害剤としてのヘテロ環状アルキル誘導体化合物及びこれを含有する薬剤学的組成物
DK3317301T3 (da) 2015-07-29 2021-06-28 Immutep Sas Kombinationsterapier omfattende antistofmolekyler mod lag-3
US20180222982A1 (en) 2015-07-29 2018-08-09 Novartis Ag Combination therapies comprising antibody molecules to pd-1
EP3878465A1 (en) 2015-07-29 2021-09-15 Novartis AG Combination therapies comprising antibody molecules to tim-3
LT3334709T (lt) 2015-08-12 2025-03-10 Incyte Holdings Corporation Lsd1 inhibitoriaus druskos
HK1254635A1 (zh) * 2015-12-17 2019-07-26 Novartis Ag C-met抑制剂与pd-1抗体分子的组合及其用途
WO2017106656A1 (en) 2015-12-17 2017-06-22 Novartis Ag Antibody molecules to pd-1 and uses thereof
SG11201806393QA (en) 2016-01-27 2018-08-30 Univ Zuerich Use of gabaa receptor modulators for treatment of itch
MD3436461T2 (ro) 2016-03-28 2024-05-31 Incyte Corp Compuși pirolotriazină ca inhibitori TAM
JP6999574B2 (ja) 2016-04-22 2022-01-18 インサイト・コーポレイション Ｌｓｄ１阻害剤の製剤
WO2017202719A1 (en) * 2016-05-23 2017-11-30 Boehringer Ingelheim International Gmbh New phenylpyrazolylacetamide compounds and derivatives as cdk8/cdk19 inhibitors
WO2018009466A1 (en) 2016-07-05 2018-01-11 Aduro Biotech, Inc. Locked nucleic acid cyclic dinucleotide compounds and uses thereof
CN106496000A (zh) * 2016-10-19 2017-03-15 蚌埠学院 一种3‑氟‑4‑溴‑苯乙酮的合成方法
SMT202100573T1 (it) 2016-12-22 2021-11-12 Calithera Biosciences Inc Composizioni e metodi per l'inibizione dell'attivita' dell'arginasi
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
WO2018237173A1 (en) 2017-06-22 2018-12-27 Novartis Ag Antibody molecules to cd73 and uses thereof
CN118307674A (zh) 2017-06-22 2024-07-09 诺华股份有限公司 针对cd73的抗体分子及其用途
SI3687996T1 (sl) 2017-09-27 2022-04-29 Incyte Corporation Soli pirolotriazinskih derivatov, ki so uporabne kot zaviralci TAM
JP7304855B2 (ja) 2017-11-14 2023-07-07 ザ チルドレンズ メディカル センター コーポレーション 新規イミダゾピリミジン化合物およびそれらの使用
CN111587114A (zh) * 2017-11-14 2020-08-25 儿童医学中心公司 用于调节人免疫应答的咪唑并嘧啶的用途
TW201922291A (zh) 2017-11-16 2019-06-16 瑞士商諾華公司 組合療法
AR113922A1 (es) 2017-12-08 2020-07-01 Incyte Corp Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
EA202091830A1 (ru) 2018-01-30 2020-12-29 Инсайт Корпорейшн Способы и промежуточные соединения для получения ингибитора jak
US12528810B2 (en) 2018-03-01 2026-01-20 Arizona Board Of Regents On Behalf Of The University Of Arizona Small molecule inhibitors of DYRK/CLK and uses thereof
MD3773593T2 (ro) 2018-03-30 2024-10-31 Incyte Corp Tratament hidradenitei supurative utilizând inhibitori ai JAK
MA52493A (fr) 2018-05-04 2021-03-10 Incyte Corp Sels d'un inhibiteur de fgfr
CR20200590A (es) 2018-05-04 2021-04-26 Incyte Corp Formas sólidas de un inhibidor de fgfr y procesos para prepararlas
CN110526916B (zh) * 2018-05-23 2021-07-13 海创药业股份有限公司 氘代Capmatinib化合物及其用途
AR126019A1 (es) 2018-05-30 2023-09-06 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
US20210214459A1 (en) 2018-05-31 2021-07-15 Novartis Ag Antibody molecules to cd73 and uses thereof
CA3101323A1 (en) 2018-06-01 2019-12-05 Incyte Corporation Dosing regimen for the treatment of pi3k related disorders
CN108530337B (zh) * 2018-06-25 2020-11-03 南华大学 一种可选择性抑制胃癌细胞的吲哚酰胺类化合物
MD3813800T2 (ro) 2018-06-29 2025-10-31 Incyte Corp Formulări de inhibitor al AXL/MER
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
WO2020047198A1 (en) 2018-08-31 2020-03-05 Incyte Corporation Salts of an lsd1 inhibitor and processes for preparing the same
CA3118093A1 (en) * 2018-09-28 2020-04-02 Arizona Board Of Regents On Behalf Of The University Of Arizona Small molecule inhibitors of dyrk1/clk and uses thereof
KR20210106437A (ko) 2018-12-20 2021-08-30 노파르티스 아게 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 및 약학적 조합물
CA3124088A1 (en) * 2018-12-20 2020-06-25 Incyte Corporation Imidazopyridazine and imidazopyridine compounds as inhibitors of activin receptor-like kinase-2
JPWO2020130125A1 (ja) 2018-12-21 2021-11-04 第一三共株式会社 抗体−薬物コンジュゲートとキナーゼ阻害剤の組み合わせ
CN113490528B (zh) 2019-02-15 2024-12-03 诺华股份有限公司 3-(1-氧代-5-(哌啶-4-基)异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
EP3924055B1 (en) 2019-02-15 2024-04-03 Novartis AG Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
US20220348651A1 (en) 2019-09-18 2022-11-03 Novartis Ag Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
BR112022010664A2 (pt) 2019-12-04 2022-08-16 Incyte Corp Derivados de um inibidor de fgfr
MX2022007759A (es) 2019-12-20 2022-07-19 Novartis Ag Combinacion del anticuerpo anti tim-3 mbg453 y anticuerpo anti tgf-beta nis793, con o sin decitabina o el anticuerpo anti pd-1 spartalizumab, para el tratamiento de mielofibrosis y sindrome mielodisplasico.
WO2021173476A1 (en) * 2020-02-24 2021-09-02 The Trustees Of Columbia University In The City Of New York Compounds, pharmaceutical formulations, and methods for treatment of cancer
EP4114401A1 (en) 2020-03-06 2023-01-11 Incyte Corporation Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
CN111825678A (zh) * 2020-06-05 2020-10-27 连庆泉 一种卡马替尼的制备方法
CN115916199A (zh) 2020-06-23 2023-04-04 诺华股份有限公司 包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案
WO2022007752A1 (zh) * 2020-07-06 2022-01-13 苏州晶云药物科技股份有限公司 苯甲酰胺类化合物及其二盐酸盐的新晶型及其制备方法
CN114621155A (zh) * 2020-12-14 2022-06-14 四川科伦药物研究院有限公司 一种制备卡马替尼的方法
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
TW202304459A (zh) 2021-04-12 2023-02-01 美商英塞特公司 包含ｆｇｆｒ抑制劑及ｎｅｃｔｉｎ－４靶向劑之組合療法
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación
CA3224341A1 (en) 2021-09-01 2023-03-09 Novartis Ag Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers
CN113896732B (zh) * 2021-10-13 2023-09-12 沈阳红旗制药有限公司 抗癌药物卡马替尼的制备方法及其应用
WO2023249994A1 (en) * 2022-06-22 2023-12-28 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
CN119654152A (zh) 2022-07-08 2025-03-18 阿斯利康(瑞典)有限公司 与hgf-受体抑制剂组合用于治疗癌症的表皮生长因子受体酪氨酸激酶抑制剂
CN116903627B (zh) * 2023-05-15 2024-01-16 云白药征武科技(上海)有限公司 一种咪唑并三嗪硫代苯甲酰胺衍生物及其制备方法和应用

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1411859A (en) 1920-12-08 1922-04-04 Marchand Robert Process for preparing hydrate of terpin
US2837520A (en) * 1955-05-26 1958-06-03 Ind Chimica Profarmaco S R L Fluorescent materials on the basis of tetrazoindenes
US4209621A (en) * 1979-04-27 1980-06-24 American Cyanamid Company (Substituted-phenyl)-1,2,4-triazolo[4,3-a]-pyrimidines and (substituted-phenyl)-1,2,4-triazolo[1,5-a]pyrimidines
US4405619A (en) * 1981-09-02 1983-09-20 Diamond Shamrock Corporation Antiinflammatory substituted-1,2,4-triazolo[4,3-b]-1,2,4-triazines
DE3311753A1 (de) 1983-03-31 1984-10-04 Hoechst Ag, 6230 Frankfurt Substituierte 6-aryl-1,2,4-triazolo(4,3-b)pyridazine - ihre herstellung und verwendung -
JPS6337347A (ja) 1986-08-01 1988-02-18 Fuji Photo Film Co Ltd 直接ポジカラ−画像形成方法
JPS63199347A (ja) 1987-02-14 1988-08-17 Konica Corp 鮮鋭性の向上した高感度ハロゲン化銀写真感光材料
JPS63310891A (ja) 1987-06-12 1988-12-19 Yoshitomi Pharmaceut Ind Ltd 縮合ピリダジン化合物
US5236917A (en) * 1989-05-04 1993-08-17 Sterling Winthrop Inc. Saccharin derivatives useful as proteolytic enzyme inhibitors and compositions and method of use thereof
JPH0313934A (ja) 1989-06-12 1991-01-22 Konica Corp ハロゲン化銀写真感光材料
IL96432A0 (en) 1989-11-30 1991-08-16 Schering Ag Pesticidal compositions containing pyridine derivatives and novel pyridine derivatives
JP2664264B2 (ja) 1990-02-15 1997-10-15 富士写真フイルム株式会社 ハロゲン化銀写真乳剤及びこれを用いた写真感光材料
FR2662163A1 (fr) 1990-05-16 1991-11-22 Lipha Nouvelles 8-amino-1,2,4-triazolo(4,3-a) pyrazines, procedes de preparation et medicaments les contenant.
JPH04251243A (ja) 1991-01-09 1992-09-07 Konica Corp ハロゲン化銀写真感光材料
FR2671551B1 (fr) * 1991-01-15 1993-03-12 Adir Nouveaux composes de structure aryl triazinique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US5232618A (en) 1991-09-30 1993-08-03 E. I. Du Pont De Nemours And Company Substantially constant boiling compositions of difluoromethane and trifluoroethane or perfluoroethane
JPH05232618A (ja) 1992-02-21 1993-09-10 Konica Corp ハロゲン化銀写真感光材料
DE4309285A1 (de) 1993-03-23 1994-09-29 Boehringer Ingelheim Kg Heterocyclen enthaltende Amidinderivate, ihre Herstellung und Verwendung
PL337888A1 (en) * 1997-07-03 2000-09-11 Du Pont Pharm Co Imidazoprimidines and imidazopyridines for use in treating neurological disorders
ES2137113B1 (es) 1997-07-29 2000-09-16 Almirall Prodesfarma Sa Nuevos derivados de triazolo-piridazinas heterociclicos.
DE19734311A1 (de) 1997-08-08 1999-02-11 Bosch Gmbh Robert Anordnung zur Übertragung optischer Signale mit Ersatzschaltungswirkung
JP4251243B2 (ja) 1998-11-26 2009-04-08 株式会社日立メディコ 領域拡張装置
JP4025468B2 (ja) 1999-07-29 2007-12-19 三井化学株式会社 有機電界発光素子
DE60018037T2 (de) 1999-11-10 2006-01-12 Ortho-Mcneil Pharmaceutical, Inc. Substituierte 2-aryl-3-(heteroaryl)-imidazo[1,2-alpha]pyrimidine und ihren verwandten arzneimittel und verfahren
CN1390217A (zh) 1999-11-12 2003-01-08 神经原公司 二环和三环杂芳族化合物
DE10010067A1 (de) * 2000-03-02 2001-09-06 Bayer Ag Neue Imidazotriazinone und ihre Verwendung
WO2001072751A1 (en) * 2000-03-29 2001-10-04 Knoll Gesellschaft Mit Beschraenkter Haftung Pyrrolopyrimidines as tyrosine kinase inhibitors
JP2001302667A (ja) * 2000-04-28 2001-10-31 Bayer Ag イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体
CA2427779A1 (en) 2000-11-10 2002-05-16 Merck Sharp & Dohme Limited Imidazo-triazine derivatives as ligands for gaba receptors
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
EE200300437A (et) 2001-03-09 2004-02-16 Pfizer Products Inc. Triasolopüridiinid kui põletikuvastased ained
GB0107751D0 (en) 2001-03-28 2001-05-16 Pfizer Ltd Pharmaceutically active compounds
CA2448076A1 (en) 2001-05-24 2002-11-28 Masahiko Hayakawa 3-quinoline-2-(1h)-ylideneindolin-2-one derivatives
DE10130167A1 (de) * 2001-06-22 2003-01-02 Bayer Ag Imidazotriazine
US20050096322A1 (en) * 2002-03-01 2005-05-05 Susumu Igarashi Nitrogen-containing heterocyclic compound
WO2003080621A1 (en) 2002-03-19 2003-10-02 Merck & Co., Inc. Process and intermediates to substituted imidazopyrimidines
US6790852B2 (en) 2002-04-18 2004-09-14 Hoffmann-La Roche Inc. 2-(2,6-dichlorophenyl)-diarylimidazoles
GB0210124D0 (en) * 2002-05-02 2002-06-12 Merck Sharp & Dohme Therapeutic agents
GB0210127D0 (en) * 2002-05-02 2002-06-12 Merck Sharp & Dohme Therapeutic agents
GB0211649D0 (en) 2002-05-21 2002-07-03 Novartis Ag Organic compounds
DE10230605A1 (de) 2002-07-08 2004-01-29 Bayer Ag Substituierte Imidazotriazine
DE10230604A1 (de) 2002-07-08 2004-01-29 Bayer Ag Heterocyclisch substituierte Imidazotriazine
MXPA05002123A (es) 2002-08-30 2005-06-06 Pfizer Prod Inc Nuevos procedimientos e intermedios para preparar triazolo-piridinas.
US6784297B2 (en) 2002-09-04 2004-08-31 Kopran Limited Process for the preparation of anti-ischemic and anti-hypertensive drug amlodipine besylate
WO2004058769A2 (en) 2002-12-18 2004-07-15 Vertex Pharmaceuticals Incorporated Triazolopyridazines as protein kinases inhibitors
UA80171C2 (en) * 2002-12-19 2007-08-27 Pfizer Prod Inc Pyrrolopyrimidine derivatives
GB0303910D0 (en) * 2003-02-20 2003-03-26 Merck Sharp & Dohme Therapeutic agents
CA2517256C (en) 2003-02-26 2013-04-30 Sugen, Inc. Aminoheteroaryl compounds as protein kinase inhibitors
PA8595001A1 (es) 2003-03-04 2004-09-28 Pfizer Prod Inc Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf)
CA2529558A1 (en) 2003-07-01 2005-01-13 Astellas Pharma Inc. Agent inducing increase in bone mass
BRPI0412003A (pt) 2003-07-02 2006-08-15 Sugen Inc arilmetil triazol e imidazopirazinas como inibidores de c-met
EP1644362A2 (en) 2003-07-02 2006-04-12 Sugen, Inc. Indolinone hydrazides as c-met inhibitors
US7122548B2 (en) * 2003-07-02 2006-10-17 Sugen, Inc. Triazolotriazine compounds and uses thereof
US7037909B2 (en) 2003-07-02 2006-05-02 Sugen, Inc. Tetracyclic compounds as c-Met inhibitors
EP1660500B1 (en) 2003-07-30 2007-12-12 Laboratorios S.A.L.V.A.T., S.A. Substituted imidazopyrimidines for the prevention and treatment of cancer
AR045595A1 (es) 2003-09-04 2005-11-02 Vertex Pharma Composiciones utiles como inhibidores de proteinas quinasas
AU2004284420A1 (en) 2003-09-24 2005-05-06 Vertex Pharmaceuticals Incorporated 4-azole substituted imidazole compositions useful as inhibitors or c-Met receptor tyrosine kinase
PT2213661E (pt) 2003-09-26 2011-12-15 Exelixis Inc Moduladores de c-met e métodos de uso
US7144889B2 (en) 2003-10-16 2006-12-05 Hoffman-La Roche Inc. Triarylimidazoles
US7169781B2 (en) 2003-10-17 2007-01-30 Hoffmann-La Roche Inc. Imidazole derivatives and their use as pharmaceutical agents
US7419978B2 (en) 2003-10-22 2008-09-02 Bristol-Myers Squibb Company Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors
GB0325031D0 (en) 2003-10-27 2003-12-03 Novartis Ag Organic compounds
WO2005073224A2 (en) 2004-01-23 2005-08-11 Amgen Inc Quinoline quinazoline pyridine and pyrimidine counds and their use in the treatment of inflammation angiogenesis and cancer
JP4932495B2 (ja) 2004-01-23 2012-05-16 アムゲン インコーポレイテッド 化合物及び使用方法
AU2005212096B2 (en) 2004-02-18 2010-12-16 Msd K.K. Nitrogenous fused heteroaromatic ring derivative
TWI378934B (en) 2004-04-02 2012-12-11 Osi Pharm Inc 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
US20050277650A1 (en) 2004-04-20 2005-12-15 Sundaram Venkataraman Process for preparing aripirazole hydrate
EP1751136B1 (en) 2004-05-07 2014-07-02 Amgen Inc. Nitrogenated heterocyclic derivatives as protein kinase modulators and use for the treatment of angiogenesis and cancer
WO2005121125A1 (en) 2004-06-09 2005-12-22 Pfizer Inc. Ether-linked heteroaryl compounds
CA2572331A1 (en) 2004-07-02 2006-02-09 Exelixis, Inc. C-met modulators and method of use
TW200613306A (en) * 2004-07-20 2006-05-01 Osi Pharm Inc Imidazotriazines as protein kinase inhibitors
EP1781654A1 (en) * 2004-07-27 2007-05-09 SGX Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
BR122020017756B1 (pt) 2004-08-26 2022-02-15 Pfizer Inc Uso de compostos de aminoeteroarila enantiomericamente puros na preparação de um medicamento para o tratamento de crescimento celular anormal em um mamífero
EP1804801A2 (en) 2004-10-15 2007-07-11 Biogen Idec MA, Inc. Methods of treating vascular injuries
EP1813613B1 (en) * 2004-11-08 2012-12-19 Msd K.K. Novel fused imidazole derivative
US7456289B2 (en) 2004-12-31 2008-11-25 National Health Research Institutes Anti-tumor compounds
WO2006076575A2 (en) 2005-01-13 2006-07-20 Bristol-Myers Squibb Company Substituted biaryl compounds as factor xia inhibitors
US20090156617A1 (en) 2005-05-12 2009-06-18 Northrup Alan B Tyrosine kinase inhibitors
US20080214562A1 (en) 2005-07-11 2008-09-04 Kristjan Gudmundsson Chemical Compounds
WO2007015866A2 (en) * 2005-07-20 2007-02-08 Kalypsys, Inc. Inhibitors of p38 kinase and methods of treating inflammatory disorders
JP2009502734A (ja) 2005-07-29 2009-01-29 アステラス製薬株式会社 Ｌｃｋ阻害剤としての縮合複素環
WO2007025090A2 (en) 2005-08-25 2007-03-01 Kalypsys, Inc. Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase
KR20080080584A (ko) 2005-11-30 2008-09-04 버텍스 파마슈티칼스 인코포레이티드 ｃ-Ｍｅｔ의 억제제 및 이의 용도
HUE030390T2 (en) 2005-12-21 2017-05-29 Janssen Pharmaceutica Nv Triazolopyridazines as tyrosine kinase modulators
SI2495016T1 (sl) 2005-12-23 2020-04-30 Ariad Pharmaceuticals, Inc. Biciklične heteroarilne spojine
WO2007096764A2 (en) * 2006-02-27 2007-08-30 Glenmark Pharmaceuticals S.A. Bicyclic heteroaryl derivatives as cannabinoid receptor modulators
US8217177B2 (en) * 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
PE20080403A1 (es) 2006-07-14 2008-04-25 Amgen Inc Derivados heterociclicos fusionados y metodos de uso
US7683060B2 (en) 2006-08-07 2010-03-23 Incyte Corporation Triazolotriazines as kinase inhibitors
CA2667453A1 (en) 2006-10-23 2008-05-02 Sgx Pharmaceuticals, Inc. Triazolo-pyridazine protein kinase modulators
BRPI0718029A2 (pt) 2006-11-06 2013-11-26 Supergen Inc Derivados de imidazo(1,2-b)piridazina e pirazolo(1,5-a)pirimidina e seu uso como inibidores da proteína cinase
ME02372B (me) * 2006-11-22 2016-06-20 Incyte Holdings Corp Imidazotriazini i imidazopiramidini kao inhibitori kinaze
CA2688823A1 (en) 2007-05-21 2008-11-27 Sgx Pharmaceuticals, Inc. Heterocyclic kinase modulators
WO2009143211A2 (en) 2008-05-21 2009-11-26 Incyte Corporation Salts of 2-fluoro-n-methyl-4-[7-(quinolin-6-yl-methyl)- imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same
EA025304B1 (ru) 2010-02-03 2016-12-30 Инсайт Холдингс Корпорейшн ИМИДАЗО[1,2-b][1,2,4]ТРИАЗИНЫ В КАЧЕСТВЕ c-Met ИНГИБИТОРОВ
CA2832994A1 (en) 2011-05-06 2012-11-15 Takasago International Corporation Ruthenium-diamine complex and method for producing optically active compound

Also Published As

Publication number Publication date
CY1116763T1 (el) 2017-03-15
KR20150014476A (ko) 2015-02-06
IL284889A (en) 2021-08-31
HK1175700A1 (en) 2013-07-12
CL2007003341A1 (es) 2008-04-18
DK3034075T3 (en) 2018-10-22
CA2669991C (en) 2016-01-26
FR22C1060I1 (fr) 2023-02-03
EA200970501A1 (ru) 2009-12-30
DK2497470T3 (en) 2015-12-07
PL2099447T3 (pl) 2013-06-28
EP3034075B1 (en) 2018-07-25
KR101532256B1 (ko) 2015-06-29
BRPI0719333A2 (pt) 2014-02-04
MY188335A (en) 2021-11-30
AR066142A1 (es) 2009-07-29
IL284889B2 (en) 2023-05-01
NZ577127A (en) 2012-03-30
SI3034075T1 (sl) 2018-12-31
PL3034075T3 (pl) 2019-03-29
FR22C1060I2 (fr) 2023-11-17
IL244244A0 (en) 2016-04-21
CY2022037I2 (el) 2023-03-24
EA201691862A2 (ru) 2017-09-29
CN103288833B (zh) 2018-01-12
DK2099447T3 (da) 2013-02-18
EP3034075A1 (en) 2016-06-22
PL2497470T3 (pl) 2016-04-29
EA032254B1 (ru) 2019-04-30
HK1136489A1 (en) 2010-07-02
ECSP099400A (es) 2009-07-31
EP2497470B1 (en) 2015-10-28
EA026126B1 (ru) 2017-03-31
NL301209I2 (nl) 2023-01-24
IL244244B (en) 2020-09-30
ES2560435T3 (es) 2016-02-19
CY1121021T1 (el) 2020-05-29
US20180282340A1 (en) 2018-10-04
US20200317680A1 (en) 2020-10-08
LUC00293I2 (me) 2024-10-04
NO2022057I1 (no) 2022-12-13
IL284889B1 (en) 2023-01-01
NO344399B1 (no) 2019-11-25
EP2099447B1 (en) 2012-11-07
US10738052B2 (en) 2020-08-11
LT3034075T (lt) 2018-11-26
SI2497470T1 (sl) 2016-02-29
US20080167287A1 (en) 2008-07-10
HK1225978B (en) 2017-09-22
CR10841A (es) 2009-06-30
US8461330B2 (en) 2013-06-11
NL301209I1 (nl) 2022-12-21
PT2497470E (pt) 2016-02-22
AU2007323725A1 (en) 2008-05-29
RS57741B1 (sr) 2018-12-31
NO346024B1 (no) 2022-01-03
RS52677B (sr) 2013-06-28
EP2497470A1 (en) 2012-09-12
US9944645B2 (en) 2018-04-17
IL276928A (en) 2020-10-29
CN101641093A (zh) 2010-02-03
MX2009005144A (es) 2009-05-27
HRP20130106T1 (hr) 2013-03-31
KR101588583B1 (ko) 2016-01-28
CA2669991A1 (en) 2008-05-29
EP3443958A1 (en) 2019-02-20
US12084449B2 (en) 2024-09-10
WO2008064157A1 (en) 2008-05-29
NO344864B1 (no) 2020-06-02
CY1117108T1 (el) 2017-04-05
JP5572388B2 (ja) 2014-08-13
ES2398843T3 (es) 2013-03-22
HUE026659T2 (en) 2016-07-28
MY188338A (en) 2021-11-30
CO6210810A2 (es) 2010-10-20
PT3034075T (pt) 2018-11-05
CY2022037I1 (el) 2023-01-27
SI2099447T1 (sl) 2013-03-29
IL198716A0 (en) 2010-02-17
LTC2099447I2 (me) 2025-04-25
NO20200077A1 (no) 2009-07-28
EA201691862A3 (ru) 2017-12-29
EP2099447A1 (en) 2009-09-16
NO20091924L (no) 2009-07-28
HRP20160077T1 (hr) 2016-02-12
US11261191B2 (en) 2022-03-01
US20110136781A1 (en) 2011-06-09
US20230002392A1 (en) 2023-01-05
TW200835481A (en) 2008-09-01
PT2099447E (pt) 2013-02-27
EP2497470B8 (en) 2015-12-02
US7767675B2 (en) 2010-08-03
US20250223291A1 (en) 2025-07-10
HUS2200052I1 (hu) 2023-01-28
ME02372B (me) 2016-06-20
JP2010510319A (ja) 2010-04-02
AU2007323725B2 (en) 2014-02-20
CN101641093B (zh) 2013-05-29
KR20090094299A (ko) 2009-09-04
US20130324515A1 (en) 2013-12-05
ES2689444T3 (es) 2018-11-14
HRP20181622T1 (hr) 2018-12-14
US20160326178A1 (en) 2016-11-10
CN103288833A (zh) 2013-09-11
TWI429432B (zh) 2014-03-11
RS54510B1 (sr) 2016-06-30
IL198716A (en) 2016-03-31
NO20190709A1 (no) 2009-07-28
IL276928B (en) 2022-03-01
GEP20125658B (en) 2012-10-10

Similar Documents

Publication Publication Date Title
ME01507B (me) Imidazotriazini i imidazopirimidini kao inhibitori kinaze
JP2010510319A5 (me)
HRP20231614T1 (hr) Spojevi pirolotriazina kao tam inhibitori
JP2013523889A5 (me)
RU2401265C2 (ru) Соединения и композиции в качестве ингибиторов протеинкиназы
JP2016517878A5 (me)
RU2012132426A (ru) ПРОИЗВОДНЫЕ ТИЕНО[3,2-d]ПИРИМИДИНА, ОБЛАДАЮЩИЕ ИНГИБИРУЮЩЕЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ ПРОТЕИНКИНАЗЫ
RU2011101901A (ru) Триазолопиридиновые соединения-ингибиторы jak и способы
JP2017530185A5 (me)
JP2016510035A5 (me)
JP2016523911A5 (me)
JP2016522246A5 (me)
JP2017505794A5 (me)
SI2797918T1 (en) Bromodomain inhibitors
RU2011125376A (ru) Способ получения соединений дигидроинденамида, фармацевтические композиции, содержащие данные соединения, и их применение в качестве ингибитора протеинкиназы
RU2009101911A (ru) Производные пиридина и пиразина в качестве ингибиторов mnk-киназы
HRP20201469T1 (hr) Derivati tetrahidroizokinolina
ME02856B (me) Aminopirimidinilni spojevi kao inhibitori jak
RU2017121044A (ru) Производные амидотиадиазола в качестве ингибиторов надфн-оксидазы
US11529350B2 (en) Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof
JP2013510876A5 (me)
RU2014120374A (ru) Имидазопиридазины
RU2013114352A (ru) Азабензотиазолы, композиции и способы применения
RU2014119254A (ru) Средства, вызывающие апоптоз, для лечения злокачественных новообразований и иммунных и аутоиммунных заболеваний
JP2009513575A5 (me)